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ABSTRACT 
Synthesis and Biological Studies of Amphiphilic Compounds Derived from Saccharides 
and Aminoglycosides 
by 
Madher N. Alfindee, Doctor of Philosophy 
Utah State University, 2019 
 
Major Professor: Dr. Cheng-Wei Tom Chang 
Department: Chemistry and Biochemistry 
 
For this dissertation research, two libraries of amphiphilic compounds were 
synthesized and biologically examined. The first library of compounds were amphiphilic 
aminoglycosides. Several aryl substituted kanamycin A derivatives were synthesized. 
This library of amphiphilic aminoglycosides was tested as antifungal agents and connexin 
inhibitors. Most of the compounds exhibited excellent fungal growth inhibition. The new 
amphiphilic kanamycins showed better connexin inhibition activity than the parent 
compound (kanamycin A) with less toxicity. 
The second series of compounds was carbohydrate esters. A regioselective one-
step esterification and scalable protocol of mono sugars was developed and used to 
synthesize a wide range of carbohydrate ester compounds. Among these compounds, 
mannose with a 14-carbon chain ester (MAN014) displayed antimicrobial activities and 
was easily produced in large quantity at relatively low cost. MAN014 was highly active 
against bacterial strains, including Staphylococcus aureus and methicillin-resistant S. 
aureus (MRSA) as well as several fungal species that included: Fusarium graminearum, 
Candida albicans, Aspergillus flavus, and Cryptococcus neoformans. MAN014 was 
iv 
 
shown to cause cell membrane permeabilization in S. aureus and F. graminearum and to 
have low toxicity toward mammalian cells. 
 
 (278 pages) 
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PUBLIC ABSTRACT 
 
Synthesis and Biological Studies of Amphiphilic Compounds Derived from Saccharides 
and Aminoglycosides 
by 
Madher N. Alfindee, Doctor of Philosophy 
Utah State University, 2019 
 
Adjacent cells communicate through gap junctions (GJs). These GJs are formed 
by head to head docking of two hemichannels (HCs) from two adjacent cells. HCs are 
connexin hexamer proteins. Connexin mutation is the most frequent cause of childhood 
hearing loss. This hearing impairment affects 2 in every 2000 children. Inhibition of the 
HCs might be the key factor to treat such disorders. A library of amphiphilic kanamycins 
was synthesized to be tested as HC inhibitors. These compounds showed excellent 
inhibition activity in comparison with the parent compound (kanamycin A) with less 
toxicity.  
A library of monosaccharide esters with varying carbon chain lengths (acetyl (C2) 
to hexadecyl (C16)) were synthesized, characterized, and tested for bioactivity. 
Carbohydrate esters showed low toxicity while remaining active against bacteria and 
fungi. The compound 6-O-tetradecanoyl-D-mannopyranose (MAN014), a mannose ester 
with a fourteen-carbon chain, showed the greatest antibacterial and antifungal properties. 
A mode of action study was tested against Staphylococcus aureus (bacteria) and 
Fusarium graminearum (fungus) and found the compound perturbed the cell membrum. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1-1 Introduction to Aminoglycosides and Kanamycins
Since the discovery of the first aminoglycoside (AG), streptomycin (figure 1-1), 
in 1944, AGs have been one of the most effective treatments for bacterial infection.1-2 
These compounds have one or more amino saccharide rings and a 2-deoxystreptamine 
ring connected together through a glycoside bond. The AGs are classified based on the 2-
deoxystreptamine (figure 1-1) ring substitution positions. The first is neomycin class 
(4,5-disubstituted 2-deoxystreptamine, such as neomycin B, paromomycin I, 
ribostamycin), and the second is kanamycin class (4,6-disubstituted 2-deoxystreptamine, 
such as kanamycin A, kanamycin B, dibekacin, tobramycin, amikacin, and arbekacin) 
(figure 1-1). In addition to these two classes, there is a monosubstituted 2-
deoxystreptamine AG such as streptomycin (figure 1-1). 
Kanamycin was first isolated from Streptomyces kanamyceticus in 1957 by 
Hamao Umezawa.3-4 This discovery was recognized as a milestone in the field of 
antibiotics due to its antibacterial potency.5 A year later, kanamycin was approved to be 
clinically used as one of the most powerful antibacterial agents, saving a tremendous 
number of lives.4 Excessive clinical chemotherapy use of kanamycin caused bacterial 
resistance to be developed 8 years after its discovery.6 Unfortunately, kanamycin became 
clinically obsolete due to the bacterial resistance.7 Reviving kanamycin activity through 
chemical modification became a primary research focus for many chemists around the 
world.8-9 
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Despite the efforts to develop novel antibacterial kanamycin analogs, only two 
compounds, amikacin in 1972 and arbekacin in 1994, were synthesized.10-12 
Subsequently, it was found that introducing a hydrophobic group to aminoglycosides 
could repurpose the compounds from being antibacterial agents to being antifungal 
agents and/or connexin inhibitors.13-14 
Figure 1-1. Structure of streptomycin, 2-deoxystreptamine, kanamycin, and neomycin 
classes 
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1-2 Project 1 Background and Rational: Antifungal amphiphilic kanamycins
The health threat of fungal infections is often underestimated by health agencies 
and the public due to the prevalence of viral and bacterial infections.15 Fungal infections 
mainly affect people with immunosuppressed systems because healthy immune systems 
are effective at clearing infections. Fungal infections are rapidly rising as a significant 
health threat in the world, since the population of immunosuppressed people is 
increasing, and fungal resistance toward antifungal agents is growing. Fungal infections 
are the leading cause of death for more than 50% of acquired immunodeficiency 
syndrome (AIDS) patients.16  Three fungal pathogens are responsible for the high 
mortality rates of AIDS patients: Aspergillus fumigatus, Candida albicans, and 
Cryptococcus neoformans.17 High mortality rates are strongly connected to fungal 
resistance and the limited number of antifungal compounds.18 To overcome this problem, 
new antifungal agents are urgently needed to help save lives. 
In 2005, Lee et al. reported moderate antifungal activity of AGs (e.g., neomycin, 
paromomycin, ribostamycin, and streptomycin).19 Meanwhile, the Chang group had built 
a vast library of amphiphilic AGs with many kanamycin-based compounds.20-21 The 
antifungal report of Lee et al. inspired us to screen our amphiphilic AG library against 
fungi. The screen identified a kanamycin B based compound, FG0822 (figure 1-2), a 
semi-synthetic compound that was active against fungi but not active against bacteria. 
FG08 inhibited the growth of Fusarium graminearum23, filamentous fungi that cause 
Fusarium head blight (FHB), a devastating disease in wheat and barley. Structurally, 
FG08 is an amphiphilic kanamycin B analog with three distinctive characteristics in the 
4 
third ring: first, the presence of an octyl group at the 4ʹʹ position, second, the presence of 
a hydroxyl group at the 3ʹʹ site, and third, the absence of an oxygen at the 6ʹʹ location. 
FG08 was synthesized via a difficult glycosylation reaction that requires extremely dry 
conditions and multiple protection steps for the amino and hydroxyl groups before the 
glycosylation as well as deprotection steps after.24-26 
The success of repurposing FG08 as an antifungal agent raised four questions 
regarding the effect of each distinctive characteristic on the antifungal activity: 1) the 
impact of the linear carbon chain length; 2) the effect of the deoxy group; 3) the impact 
of the alkyl group location; and 4) the effect of the 3ʹʹ hydroxyl group. These questions 
were answered through a structure-activity relationship (SAR) study. 
The carbon chain length impact was determined through the synthesis of three 
compounds: FG01 with a butyl substitute, FG02 with a dodecyl substitute, and FG05 
with a hexyl substitute (figure 1-2).22, 27 These compounds were biologically less active 
than FG08, which had an octyl substitute. This showed that the octyl substitution is 
optimal for antifungal activity. 
The effect of the deoxy group at site 6ʹʹ was evaluated by adding a hydroxyl group 
at that location to produce FG03 (figure 1-2). The antifungal activity of this compound 
was similar to FG08, which indicates that the deoxy group has a minor influence on 
antifungal activity. 
The third part of the SAR study was to examine the effect of the hydroxyl group 
at the 3ʹʹ position on antifungal activity by replacing the hydroxyl group with an amine 
group to produce FG15 (figure 1-2). This compound had a comparable antifungal activity 
5 
Figure 1-2. Structures of  FG compounds and K20. 
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to FG08, which indicates that the hydroxyl group has a minor influence on antifungal 
activity. 
Finally, the effect of the alkyl chain location was evaluated by synthesizing FG06 
with an octyl substitute at the 4ʹʹ position, FG07 with an octyl substitute at the 3ʹʹ 
position, FG09 with an octyl substitute at the 2ʹʹ site, FG12 with an octyl substitute at the 
3ʹ location, and FG13 with an octyl substitute at the 4ʹ position (figure 1-2). These 
compounds are less active than FG08, except compound FG06, which has comparable 
antifungal activity to FG08. The fungal growth inhibition of the FG06 shows that the 
optimal substitution site is the 4ʹʹ position followed by the 6ʹʹ location. However, FG08 
can be synthesized only in a small quantity (mg scale) due to the complexity of the 
glycosylation reaction as well as the multiple protection and deprotection steps. The 
limited amount of FG08 makes agricultural field studies and medical testing not 
practical. 
Inspired by the antifungal results of FG06 and the need to devise a large-scale 
synthesis of amphiphilic kanamycin compounds to make wide usage practical, we 
developed a direct modification protocol for the second generation of amphiphilic 
kanamycin analogs.28 Using this protocol, we synthesized a library of kanamycin A 
analogs substituted at the 6ʹʹ position with various alkylsulfonyl groups. These 
compounds were tested against a panel of bacteria and fungi. Among them, K20, which 
has an octansulfonyl group (figure 1-2), was the most active compound against fungi but 
did not have any bacterial growth inhibition. 
Our group previously studied the effect of four carbon chain lengths: butyl (C4) at 
the 4ʹʹ position, hexyl (C6) at 6ʹʹ the position, octyl (C8) at the 4ʹʹ position, and dodecyl 
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(C12) at the 4ʹʹ position on antifungal activity. We showed that the octyl group is the 
optimal carbon chain for an antifungal agent. However, we did not study the effect of 
other carbon chains. Therefore, we built a new library of amphiphilic kanamycins using a 
novel three product protocol, starting from a butyl (C4) up to a hexadecyl (C16) (scheme 
1-1). In this protocol, a regioselective direct modification of tetraazidokanamycin A is
performed using alkyl bromide and sodium hydride. The protocol outcomes are a 4ʹʹ, 6ʹʹ 
dialkylated tetraazidokanamycin A (K46), a 4ʹʹ mono-alkylated tetraazidokanamycin A 
(K4), and a 6ʹʹ mono-alkylated tetraazidokanamycin A (K6). 
Several studies, focused on cell membrane permeability, were performed to 
evaluate the mode of action for amphiphilic aminoglycosides.29-31 Non-membrane 
permeable dyes, SYTOXTM green or propidium iodide (PI), were used in these studies. 
These dyes enter the cell only if the cell membrane integrity has been compromised by an 
agent, such as an amphiphilic aminoglycoside.32-33 Before entering the cell, these dyes are 
non-fluorescent, and upon entering the cell, these dyes will emit fluorescence after they 
bind to the nucleic acids. 
Fosso et al. reported that kanamycin B amphiphilic analogs can affect the cell 
membrane integrity of Candida albicans ATCC 64124 by using PI dye. These analogs 
had a dodecyl (C12) and a tetradecyl (C14) carbon chains attached to kanamycin B at the 
6ʹʹ position through thioether linkage.31 In another study, Subedi et al. reported that 
Candida albicans MYA 2876 membrane integrity can be affected by an amphiphilic 
kanamycin A analog. This compound had an octyl (C8) group substituted at 6ʹ via amide 
linkage.34 
8 
Scheme 1-1. 
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1-2.1 Project 1: Aims and Objectives for Amphiphilic Kanamycins as Antifungals
This project aims to test the antifungal activity of the new amphiphilic 
kanamycins against a panel of fungal strains and evaluate the mode of action of these 
compounds by using non-permeable SYTOXTM green and PI dyes through time-based 
kinetic membrane permeabilization studies and fluorescence images. 
The project objectives are to answer questions regarding new amphiphilic 
kanamycins: 1) Do aryl substituted kanamycin compounds have similar antifungal and 
antibacterial profiles to alkyl substituted kanamycins? 2) How do the electric effects of 
the aryl substitution affect antifungal activity? 3) Does the degree of hydrophobicity 
affect antifungal activity? 
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1-3 Project 2 Background and Rationale: Amphiphilic Kanamycins as Connexin
Inhibitors 
 Communication between the adjacent cells is crucial to regulate cell tasks such as 
growth, embryogenesis, and homeostasis and its accomplished by transferring ions, 
metabolites, and small molecules.35 This communication is mediated by protein channels 
called gap junction channels (GJCs) (figure 1-3).36-37 Each GJC is formed by a head to 
head connection of two trans-membrane hemichannels (HCs) (figure 1-3) with one HC 
from each cell.38-39 An HC can pair with a neighbor cell HC to form a GJC or remain 
unpaired (free).40-41 HC is a hexamer of connexins; each connexin (figure 1-4) is built 
from four helical subunits (i.e., M1, M2, M3, and M4).42 These subunits have two 
extracellular loops called extracellular loop 1 (EL1) and extracellular loop 2 (EL2) 
 Figure 1-3. Gap junction channels (GJCs) and hemichannels (HCs). 
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with three cytoplasmatic domains (N-terminal, C-, and cytoplasmatic loop (CL)).43 In 
mammals, there are more than 20 known connexins with variable functions and they are 
named based on the molecular wieght.44-47 For example, connexin with ~ 26 kDa is 
named Cx26.48  
 Connexins are oligomerized to form HC at different areas in the cell depending on 
the connexin type; for instance, Cx32 is oligomerized in the endoplasmic reticulum/Golgi 
area while Cx43 is oligomerized in the Golgi network.49 After oligomerization, the HC is  
Figure 1-4. Connexin subunits 
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transferred and inserted into the cell membrane while it is in a closed configuration.48, 50 
HC remains closed most of the time until it is paired with HC from another cell to build 
at GJC.51  
 Recent studies showed that closed HC could open to contribute in the exchange of 
essential molecules such as ATP, NAD+, and glutamate with the extracellular 
environment.40, 48, 50, 52-53 Uncontrolled opening of these free HCs causes cell fluids to 
leak, which might lead to cell damage and death.54 The uncontrolled opening of 
undocked HCs is strongly believed to be one of the significant causes for non-syndrome 
human disorders such as child hearing loss.41  
 Hearing is a complex process that requires many cell types from many tissues inside 
the inner ear.55 Communication between these cells through GJC is essential for the 
hearing process. Hearing is an essential sense for vertebrates and is necessary to develop 
and acquire language in young children.56 In the US, newborn hearing loss afflicts almost 
2 per 1000 children, of which 15 percent are due to connexin Cx26 mutations in the inner 
ear. Molecules that prevent the opening of HCs, hereafter called HC inhibitors, could be 
invaluable in prevent and treating disorders caused by connexin mutations. 
 Identifying HC inhibitors will be vital toward finding treatment for disorders caused 
by connexins mutations.57 Currently, few compounds have been used as HC inhibitors in 
research (e.g., glycyrrhetinic acid and its derived compound carbenoxolone, quinine, 
mefloquine, and 2-Aminophenoxyborate) (figure 1-5).58-61 These compounds have been 
found to inhibit both HC and GJC with no selectivity for one over the other.62-63 Using 
peptides as inhibitors has shown to be more selective. However, their mechanism of 
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action and their activity in different settings still unclear.64 
Figure 1-5. Structures of connexin inhibitors 
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 In contrast, the AG gentamicin (figure 1-6) has shown good selectivity of inhibiting 
HC without affecting GJC while having good half maximal inhibitory concentration 
(IC50) at 133.4 µM.65 Moreover, commercially available AGs [i.e., kanamycin A, 
kanamycin B, geneticin (figure 1-6), neomycin, and paromomycin] were tested as HC 
inhibitors using a recently developed protocol.37, 58, 66 These compounds were found to 
inhibit connexins (IC50 = 0.44 µM – 42 µM). Nevertheless, AGs still have toxicity, which 
has limited their use while amphiphilic aminoglycosides (AAG) have shown less toxicity 
making them more attractive connexin inhibitor candidates.  
Figure 1-6. Gentamicin and geneticin structures 
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1-3.1 Project 2: Aims and Objectives for Amphiphilic Kanamycins as Connexin
Inhibitors. 
The aims of project 2 are to test the inhibitory effects of the 4ʹʹ and 6ʹʹ diarylated 
amphiphilic kanamycins on connexin Cx26 activity. Other aims are to evaluate the 
antibacterial activities against a panel of bacterial strains and to examine the cytotoxicity 
of these compounds. 
The objectives of this project are to perform complete structure activity relationship 
study to elucidate the effect of two types of substituents, alkyl and aryl on the connexin 
inhibition activity. 
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1-4 Introduction to Carbohydrate Esters and Antimicrobial Food Additives.
1-4.1 Project 3 Background and Rational
 Antimicrobial food preservatives are chemical compounds that are added to food to 
prevent spoilage and/or preventing food contamination with pathogenic microbes. 
Compounds such as sodium benzoate and sodium sorbate are used as antimicrobial food 
preservatives.  
 Sodium benzoate is listed as “generally regarded as safe” (GRAS) by the U.S. Food 
and Drug Administration (FDA).67-68 It is widely used as a food preservative especially 
for acidic foods such as soft drinks and jams, and is also common in medicine.69 
Nevertheless, this compound is not entirely safe. It has been reported that traces of 
carcinogenic benzene has been found in soft drinks, which indicates decarboxylation of 
sodium benzoate has occurred.70-72 
 Sodium sorbate is used as a preservative in ketchup, meat, cheese, and mayonnaise.73 
This compound has been banned by the European Food Safety Authority (EFSA) from 
being used as a food preservative because of its possible genotoxic properties.73 Sodium 
sorbate is still permitted as a food preservative in the US, Australia, Canada, and New 
Zealand.74 Due to the potential health issues of these common preservatives, there is 
growing interest in developing new antimicrobial food additives.75 
 Carbohydrate esters (CE) are class of amphiphilic compounds that have a wide range 
of applications.76-79 These compounds are tasteless, odorless, non-toxic, and non-irritating 
and can be degraded by organisms into a sugar and a fatty acid, which are safe and 
nutritional.80-82 Sucrose mono, di, and triesters are already approved by the FDA to be 
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used as emulsifiers in food and medicine.83 The sucrose esters world annual production is 
4000 tons, the highest among the CE.  
 Some CEs have been reported as possessing antimicrobial properties.84-85 A library 
of sucrose stearate (C18), sucrose laurate (C12), sucrose caprate (C10), maltose caprate 
(C10), fructose caprate (C10), and glucose caprate (C10) were reported.79 These esters 
were tested against five food pathogens: Escherichia coli AS1.90, Salmonella 
typhimurium AS1.1174 (gram-negative bacteria), Staphylococcus aureus AS1.89, 
Bacillus subtilis AS1.1849, and Bacillus cereus AS1.1846 (gram-positive bacteria). 
Sucrose caprate was the most active compound against these strains.  
 In another study, a series of CEs derived from glucose and mannose with various 
fatty acids were synthesized.86 Testing of the CEs toward different S. aureus bacterial 
strains [ ATCC 25923, NCTC 1803, methicillin resistance S. aureus (MRSA) ATCC 
33591, MRSA ATCC 33592, and MRSA ATCC 43300] showed that methyl 6-O-lauroyl-
β-D-glucopyranoside was the most active compound. Furthermore, the mode of action 
study for glucose derived compounds showed that these CEs are membrane disrupters.  
 All the reported CEs are acylated at the primary hydroxyl group on the carbohydrate. 
Saccharides have multiple secondary hydroxyl groups with one or more primary 
hydroxyl groups. The primary hydroxyl group is slightly more reactive than the 
secondary hydroxyl groups, but selective acylation at that primary hydroxyl group is 
challenging through conventional chemical synthesis route, and it is not challenging 
through the enzyme-catalyzed reactions.87 In conventional CE chemical synthesis, 
selective acylation can be achieved by protecting the secondary hydroxyl groups leaving 
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the primary hydroxyl group free for esterification then deprotection.84, 88 This process is 
not economic because it needs more time, chemical reagents, and labor. 
 In the industry, CEs are chemically synthesized using high temperatures (i.e., 100 to 
185 ̊C).89 Using high temperatures produce byproducts with multi degree of 
esterification. These byproducts require separation that add cost to the overall process. 
 Enzymes such as lipase have been used as catalysts for CE synthesis reactions via 
esterification of a carbohydrate with a fatty acid and transesterification of a sugar with a 
vinyl fatty acid ester. These are one step reactions with very high acylation 
regioselectivity at the primary hydroxyl group.89 Enzyme catalyzed synthesis reactions 
need mild pH (6.3 to 8.0) and temperature (37 to 57  ̊C) conditions. However, this method 
of CE synthesis has three drawbacks that limit it application in synthesis of CEs: viable 
solvents, dry reaction conditions, and substrate specificity.  
 The solvent choice is a significant challenge. It should dissolve a polar carbohydrate 
and a nonpolar fatty acid or fatty acid vinyl ester as well as the enzyme itself. In many 
cases, solvents that can dissolve both of the substrates such as N,N-dimethylformamide 
(DMF) or pyridine, which might reduce the enzyme activity.90  
 Lipase usually catalyzes ester hydrolysis to a fatty acid and an alcohol, but it also 
can catalyze ester formation (reversing the reaction) under anhydrous solvent 
conditions.91 Under these conditions, the lipase has high substrate specificity which can 
be seen in the variable reaction yields for variable sugar and variable carbon chain 
lengths.92 
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1-4.2 Project 3: Aims and Objectives for CEs as Antimicrobial Food Additives
 This work is aimed at finding and developing a protocol that combines advantages 
from both chemical and enzymatic CE synthesis. The protocol should be done in short 
reaction steps to be economical in terms of cost and labor, and it should be applicable for 
a wide range of sugars. In addition to that, it should have high selectivity for the primary 
hydroxyl group over the secondary hydroxyl groups and should be scalable for  large 
scale syntheses.  
 The objectives are to study the structure-activity relationship (SAR) for different 
mono sugars with different acyl carbon chain lengths. The synthesized CE compounds 
can help to identify the optimal mono sugar and the optimal carbon chain (lead 
compound) after screening the biological activities of these CEs against a panel of 
bacterial and fungal strains. The lead compound can be further tested against mammalian 
cells to ensure it is not toxic and it might be an excellent candidate to be an antimicrobial 
food additive. 
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CHAPTER 2 
ANTIFUNGAL ACTIVITIES OF 4″,6″-DISUBSTITUTED AMPHIPHILIC 
KANAMYCINS a 
2-1 Abstract
Amphiphilic kanamycins derived from the classic antibiotic kanamycin have 
attracted interest due to their novel bioactivities beyond inhibition of bacteria. In this 
study, the recently described 4″,6″- diaryl amphiphilic kanamycins reported as inhibitors 
of connexin were examined for their antifungal activities. Nearly all 4″, 6″-diaryl 
amphiphilic kanamycins tested had antifungal activities comparable to those 4″, 6″-
dialkyl amphiphilic kanamycins, reported previously against several fungal strains. The 
minimal growth inhibitory concentrations (MICs) correlated with the degree of 
amphiphilicity (cLogD) of the di-substituted amphiphilic kanamycins. Using the 
fluorogenic dyes, SYTOXTM green and propidium iodide, the most active compounds at 
the corresponding MICs or 2×MICs caused biphasic dye fluorescence increases over time 
with intact cells. Further lowering the concentrations to half MICs caused first order 
fluorescence increases. Interestingly, 4×MIC or 8×MICs levels resulted in fluorescence 
suppression that did not correlate with the MIC and plasma membrane permeabilization. 
The results show that 4″,6″-diaryl amphiphilic kanamycins are antifungal and that 
amphiphilicity parameter cLogD is useful for the design of the most membrane-active 
versions. A cautionary limitation of fluorescence suppression was revealed when using 
fluorogenic dyes to measure cell-permeation mechanisms with these antifungals at high 
concentrations. Finally, 4″,6″-diaryl amphiphilic kanamycins elevate the production of 
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cellular reactive oxygen species as other reported for amphiphilic kanamycins. 
a Adapted from (AlFindee, M. N.; Subedi, Y. P.; Grilley, M.; Takemoto, J. Y.; Chang, C.-W. T. 
“Antifungal activities of 4″,6″-disubstituted amphiphilic kanamycins” Molecules. 2019, 24(10), 1882). 
Copyright © 2019, MDPI. 
2-1 Introduction
Although commonly unappreciated, fungal diseases cause tremendous economic 
loss and health impacts globally. Annually, more than a billion people acquire fungal 
infections. The death rate from fungal diseases is equal to that of tuberculosis and malaria 
combined, with approximately 10% of those deaths due to cryptococcal meningitis 1-2. 
Immunosuppressed individuals, such as those infected with HIV or undergoing treatment 
for cancer or organ transplants, are especially susceptible to invasive fungal infections. 
Current treatment options for fungal infections include polyene-based compounds (e.g., 
amphotericin B) [3–5], cytosine-based compounds (e.g., flucytosine) [5,6], and azole-
based compounds (e.g., itraconazole and fluconazole) [5,7,8]. However, as exemplified in 
the recent outbreak of Candida auris [9], drug resistance is a growing problem. Further 
research to develop new and effective treatments for fungal diseases is urgent. 
Kanamycin belongs to a class of antibacterial compounds known as 
aminoglycosides that are active against both Gram-negative (G-) and Gram-positive (G+) 
bacteria, albeit its clinical use is limited due to the emergence of bacterial resistance 
(Figure 2-1) [10]. To overcome the problem of bacterial resistance, extensive research 
has been devoted to structural modifications of aminoglycosides that lead to the 
discovery of amphiphilic aminoglycosides [11,12]. In contrast to antibacterial kanamycin 
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that is inactive against fungi, some of the amphiphilic kanamycins (AKs) were found to 
be active against a wide range of fungal strains [13,14] and concomitantly not active 
against bacteria. Two of the antifungal AKs produced good specific antifungal activity - 
FG08, which contains an octyl group (C8) chain attached at the 4ʺ position of kanamycin 
analog via an ether linkage [15] and K20, which has an octanesulfonyl group at the 6″ 
position (Figure 2-1) [16]. 
Figure 2-1. Structure of aminoglycosides and selected kanamycins (AKs). 
AKs are known to show their antimicrobial activity by increasing the membrane 
permeability of microorganisms [17–21]. Fluorogenic dyes, such as SYTOXTM green and 
propidium iodide (PI), are commonly employed for the study of membrane 
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permeabilization (Figure 2-2). SYTOXTM green is non-fluorescent and cannot penetrate 
the plasma membrane of intact organisms. However, in the presence of agents that 
compromise membrane integrity, SYTOXTM green enters the cytoplasm, binds to nucleic 
acids, and emits fluorescence. Propidium iodide (PI) has similar properties and is widely 
used for evaluating membrane permeabilization of substances in fungi and bacteria.  
We recently reported the synthesis of 4″,6″-diaryl AKs (compounds 1 – 8) as 
connexin inhibitors [22,23] (Figure 2-3). Since these are structurally similar to the 
antifungal 4″,6″-dialkyl AKs (compounds 9 – 13), we decided to investigate their 
antifungal activities and to conduct mode of action studies of both groups of compounds 
using fluorogenic dyes. 
Figure 2-2. Structures of SYTOXTM green and propidium iodide (PI). 
37 
Figure 2-3. Structure of selected AKs. 
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2-2 Results and Discussion
2-2.1. Fungal Growth Inhibition by 4″,6″-Disubstituted AKs
Thirteen disubstituted AKs were examined for growth inhibition capabilities 
against a panel of fungi that included yeasts and the filamentous fungus Fusarium 
graminearum (Table 2-1). The 4″, 6″- diaryl compounds 6, 7, and 8 were strongly 
inhibitory toward F. graminearum (minimal growth inhibitory concentrations, MICs, 2 – 
16 µg/mL) and compounds 1– 5 had low (MICs, >32 µg/mL) to moderate (MICs, 16 – 32 
µg/mL) inhibitory activities. Likewise, except with compounds 1 and 2, Cryptococcus 
neoformans H99 and C. neoformans VR-54 were highly susceptible to the diaryl 
compounds (MICs, 2 – 16 µg/mL) as was Rhodotorula pilimanae (ATCC 26423) (MICs, 
2 – 32 µg/mL). In contrast, except with compounds 4 and 6, Candida albicans 64124 
(azole-resistant) and C. albicans MYA2876 (azole sensitive) were not susceptible to the 
diaryl compounds (MICs, >32). The 4″, 6″-dialkyl compounds, except 13, displayed 
strong inhibitory activities against the C. neoformans strains (MICs, 2 – 16 µg/mL), and 
moderate activities against Candida strains 64124 and MYA2876 (MICs, 8 – 128 
µg/mL). Compound 13, with a long linear alkyl chain (C16), had no antifungal activity 
(MICs, = or >256). Overall, except for compounds 1, 2 and 13, the 4″, 6″-disubstituted 
AKs (10 of 13) were strongly inhibitory to F. graminearum, C. neoformans and R. 
pilimanae (ATCC 26423), but less so or moderately with the C. albicans strains. 
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Table 2-1. Minimal growth inhibitory concentrations (MICs) of AKs against fungal 
strains 
Compound cLogD 
Strains 
A B C D E F 
1 -10.32 32-64 256 256 32 64 128 
2 -9.81 256 256 >256 32 64 64 
3 -8.88 64-128 >256 256 8 16 32 
4 -9.53 16-32 32-64 32-64 4 8 16 
5 -8.77 16-32 64 128 4-8 8 8 
6 -7.81 4-16 32-64 64 2-4 8 8 
7 -7.81 4-8 128 128 8-16 4 8 
8 -6.44 2-8 128-256 256 8-16 4 2-4
9 -9.36 32 32 16-32 8-16 8 8
10 -8.57 32 ND 8-16 2 4 2
11 -7.78 16 ND 128 8-16 8 8-16
12 -6.99 ND 8 16-32 4 4 4
13 -1.44 >256 >256 >256 >256 256 >256
K20 -11.62 32 16 32 8-16 8 16
MIC unit: µg/mL; ND: Not determined; Strains; (A) Fusarium graminearum B4-5A, (B) 
Candida albicans 64124, (C) Candida albicans MYA-2876, (D) Rhodotorula Pilimanae 
(ATCC 26423), (E) Cryptococcus neoformans H99, (F) Cryptococcus neoformans VR-
54.
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2-2.2. Analysis of Correlation Between MIC and cLogD
Structurally diverse AKs have been synthesized for the purpose of elucidating 
structure-activity relationships (SAR) [7,20]. These AKs carry variations of hydrophobic 
moieties or linkages of the hydrophobic moieties to the kanamycin core. Several factors 
that may contribute to the differences of antimicrobial activity, such as the chain length 
of the hydrophobic moiety and the linkage, were deduced primarily on the revealed MICs 
of these AKs. Despite these labor-intensive efforts, contradictory SARs were noted, and 
these factors seemed to escalate the complexity in understanding the nature of the 
antimicrobial selectivity of AKs. Thus, we explored the use of a water/1-octanol 
distribution coefficient (cLogD) as a simplified means to evaluate the amphiphilicity of 
the disubstituted AK compounds and possible correlation with antifungal activity. The 
cLogD was calculated using Marvin Sketch (version 18.19) keeping a 0.1 molar 
concentration of Na+, K+, and Cl- ions (Table 1). When plotting cLogD (x-axis) vs. MICs 
(y-axis) for all tested fungi (z-axis), a clearer SAR was observed (Figure 2- 4). 
Compounds with cLogD values between -9.5 and -6.4 had the lowest MIC values against 
F. graminearum, C. neoformans (two strains) and R. pilimanae. cLogD values above
(e.g. compound 13) or below (e.g., compounds 1 and 2) this range corresponded to the 
highest MIC values. Such a trend was not observed with C. albicans (two strains) 
because of fluctuating MIC values. This analysis suggests that it is possible to use cLogD 
as a guideline for designing antifungal AK of the same class, which can drastically 
reduce the synthetic burden. 
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Figure 2-4. Relationship of (cLogD) VS. MIC 
2-2.3. Plasma Membrane Permeabilization of 4″,6″-Disubstituted Kanamycins
Plasma membrane permeabilization studies were conducted by light microscopy 
using the dyes SYTOXTM green with C. neoformans H99 treated with diaryl compound 7 
or the dialkyl compounds (11 and 13) at 1×MIC (Figure 2-5). Triton X-100 (1%), a non-
fungal targeting agent, but known to cause membrane permeabilization of mammalian 
cells, was used for comparison. As expected, most fungal cells treated with compounds 7 
and 11 showed fluorescence emitted from SYTOXTM green. In contrast, almost no cells 
emitted fluorescence when treated with compound 13 (256 µg/mL). A few fungal cells 
emitted fluorescence when treated with Triton X-100, suggesting that this agent at 1% 
concentration causes a small degree of membrane permeabilization. 
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Figure 2-5. Phase contrast (left panels) and fluorescent images (right panels) of C. 
neoformans H99. (A) and (B): Images of cells treated with SYTOXTM green alone; (C) 
and (D): Images of cells treated with SYTOXTM green and 1% Triton X-100; (E) and (F): 
Images of cells treated with SYTOXTM green and compound 7 (1x MIC); (G) and (H): 
Images of cells treated with SYTOXTM green and compound 11 (1x MIC); (I) and (J): 
Images of cells treated with SYTOXTM green and compound 13 (256 µg/mL). 
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We previously reported that fungi treated with active AKs with hydrophobic groups 
attached at the 6′ position displayed a fast increase of dye fluorescence observed in a 
time-dependent fashion [24]. To determine if the disubstituted AKs behave similarly, 
time-dependent kinetic membrane permeabilization experiments were performed using C. 
neoformans H99 fungi at 1×MIC of the AKs. The relative fluorescence unit (RFU) was 
monitored every 3 min for 4 h. 
The most growth inhibitory 4″,6″-disubstituted AKs (compounds 5, 6, 7, and 8) 
caused the highest levels of SYTOXTM green fluorescence. For most of the tested 
compounds, the kinetics of the fluorescence signals revealed biphasic fluorescence 
increases over time: A fast membrane permeabilization within the first 15 min that 
quickly levels to various RFUs (Figure 2-6). The leveled units, in general, follow similar 
orders in all experiments using SYTOXTM green or PI. The less active AKs (1, 2 and 3) 
showed profiles similar to Triton X-100. Despite the overall similarities of the biphasic 
fluorescence profiles, differences were observed between the profiles. First, different 
total RFU levels (at 4 h) were achieved with different AKs and with the two dyes despite 
using the same fungal cell densities, fluorogenic dye concentrations, and compounds at 
1×MIC. Second, in three experiments (Figure 2-6B – D), several AKs caused total RFU 
levels lower than controls with no AK. Third, certain compounds displayed different 
RFU kinetic profiles using SYTOXTM green vs PI. For example, the RFU kinetic profiles 
of compounds 2 and 4 appeared flat or linear using PI (Figure 2-6B) but biphasic using 
SYTOXTM green (Figure 2-6A). For compounds 5 and 6, different RFU profiles were 
obtained from the experiments using SYTOXTM green vs. PI. For compound 12, the RFU 
profiles were linear using SYTOXTM green but biphasic using PI (Figure 2-6C, D). 
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Because the only variable parameters in these experiments were the individual AKs and 
their MICs, it was speculated that the fluorescence properties of the dyes reflected in the 
RFU and kinetic profiles were directly affected by individual AKs and their 
concentrations. To explore this hypothesis, we carried out further experiments using 2-
fold adjusted concentrations of the MICs of the AKs. 
Figure 2-6. Kinetic membrane permeabilization of C. neoformans H99. (A) Cells treated 
with 4″,6″-diaryl AKs using SYTOXTM green; (B) cells treated with 4″,6″-diaryl AKs 
using PI; (C) cells treated with 4″,6″-dialkyl AKs using SYTOXTM green; (D) cells 
treated with 4″,6″-dialkyl AKs using PI. The figure with standard deviation is available in 
figure A-1. 
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Fluorescence kinetics and levels with selected 4″, 6″ disubstituted AKs at various 
concentrations were measured with C. neoformans H99 using SYTOXTM green and PI 
(Figure 2-7). It was observed that the AK concentration significantly influenced the 
degree of fluorescence independently of MIC and membrane permeabilization 
capabilities. For example, compound 7 showed linear fluorescence kinetics at 0.5×MIC, 
biphasic kinetics at 1×MIC, biphasic kinetics but leveled at lower RFUs at 2×MIC, and 
suppression at 4×MIC and 8×MIC (Figure 2-7A,B).  The same trend was observed when 
using PI. For compound 10, similar kinetic profiles were obtained at 1×MIC but not 
when 2×MIC was employed (Figures 2-7C,D). The kinetic RFU profiles of compound 11 
behaved like those of compound 7 (Figure 2-7E,F). These data support our speculation 
that the fluorescence of dyes can be affected by the concentration of the tested AK 
compounds. 
Images of fungi treated with compound 11 provide further evidence for the direct 
effect of the AK concentration on fluorescence (Figure 2-8). Cells treated with compound 
11 and PI for 2 h, emit fluorescence at 0.5x and 1×MICs but little or no fluorescence at 
8×MIC. A similar result was obtained with SYTOXTM green. 
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Figure 2-7. Kinetic membrane permeabilization using various concentrations of AKs. 
(A): Cells treated with compound 7 using SYTOXTM green; (B): Cells treated with 
compound 7 using PI; (C): Cells treated with compound 10 using SYTOXTM green; (D): 
Cells treated with compound 10 using PI; (E): Cells treated with compound 11 using 
SYTOXTM green; (F): Cells treated with compound 11 using PI. The figure with standard 
deviation is available in figure A-2. 
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Figure 2-8. Images of C. neoformans treated with varied concentrations of compound 11. (A1, 
A2) Cells treated with only SYTOXTM green; (B1, B2) cells treated with Triton X-100 
and SYTOXTM green; (C1, C2) cells treated with 0.5×MIC of 11 and SYTOXTM green; 
(D1, D2) cells treated with 1×MIC of 11 and SYTOXTM green; (E1, E2) cells treated with 
2×MIC of 11 and SYTOXTM green; (F1, F2) cells treated with 4×MIC of 11 and 
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SYTOXTM green; (G1, G2) cells treated with 8×MIC of 11 and SYTOXTM green; (H1, 
H2) cells treated with only PI; (I1, I2) cells treated with Triton X-100 and PI; (J1, J2) 
cells treated with 0.5×MIC of 11 and PI; (K1, K2) cells treated with 1×MIC of 11 and PI; 
(L1, L2) cells treated with 2×MIC of 11 and PI; (M1, M2) cells treated with 4×MIC of 11 
and PI; (N1, N2) cells treated with 8×MIC of 11 and PI. 
These results indicate that there is an optimal ratio of AK vs. fluorogenic dye when 
measuring plasma membrane permeabilization by AK compounds. By considering the 
MICs that gave rise to the maximum leveled RFU, the concentration fell in the region 
around 5 µM of AK and 0.01 µM of SYTOXTM green or 0.4 µM of PI. Judging from the 
structures of the AKs, SYTOXTM green and PI (Figure 2-2), it is likely that ionic or 
hydrogen bonding contribute to the AK inhibiting effect toward these fluorogenic dyes. 
Therefore, caution needs to be taken when evaluating the cellular effect of AKs or other 
classes of compounds using fluorogenic probes. Finally, since high RFUs were observed 
with the use of AK levels at < 1x MIC, possibilities are opened for using such low AK 
concentrations to detect fungi without significant fungicidal effect. 
2-2.4. Effect of 4″,6″-Disubstituted Kanamycins on the Production of Reactive Oxygen
Species
It has been reported that a wide range of antimicrobials of different classes, albeit 
having various modes of action, will have a common effect of increased oxidative stress 
by promoting the production of reactive oxygen species (ROS), which can lead to cell 
death. We have also demonstrated that 6′-substituted AKs exert this common effect. 
Thus, several selective 4″,6″-disubstituted kanamycins, compounds 4, 7 and 11, were 
subjected to the investigation of induced ROS production. The experiments of ROS 
production were conducted using 1,1'-(hexane-1,6-diyl)bis(3-decyl-4,9-dioxo-4,9-
49 
dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium triflate (14) (Figure 2-9) [25,26], known 
to produce ROS, as the positive control. Compound 4 showed almost no ROS generation 
as compared to control, while compound 11 showed moderate ROS generation, and 
compound 7 showed a much higher level of ROS generation (Figure 2-9). 
Figure 2-9. ROS study for 4″,6″-disubstituted AKs and compound 14 structure 
Compound 7 contains a naphthalene motif that can better stabilize radicals. Hence, 
it explains why compound 7 promoted ROS production to the level of the positive 
control, compound 14. Compound 11, with the linear alkyl chain, exerted a moderate 
level of ROS production similar to the 6′-alkylated AKs as we have noted previously. 
Fluoro substituted molecules, such as in the case of compound 4, are noted to inhibit the 
formation of radicals [27]. Therefore, it is not surprising that compound 4 displayed 
almost no elevation of ROS production as compared to the control (blank). However, 
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compound 4 showed similar antifungal activities as compounds 7 and 11. The ROS 
measurement was conducted following 3 h of incubation of fungi with the AKs, a much 
shorter time compared to the determination of the MIC, which often requires 48 h of 
incubation. Thus, compound 4 may exert fast membrane permeabilization, as observed 
with the fast RFU increases. However, the presence of fluoro substituents deters the 
formation of ROS resulting in the lower ROS generation but similar antifungal activity. 
Hence, it is likely that the actual mode of the antifungal mode of action is a combination 
of two main factors: (1) The rate of membrane permeabilization and 2) the rate of ROS 
production 
2-3. Materials and Methods
Procedure for the antifungal activity. The fungal MIC test was carried out 
similar to previously reported protocols [28]. In brief, fungi were grown in RPMI 1640 
medium for 48 h at 37 °C. Cells, or spores in the case of F. graminearum were counted 
and diluted to 4×104 cells/mL in the growth medium. Fungi were added to the 
compounds dissolved in growth medium maintaining final concentrations of the 
compounds from 256 to 0.125 µg/mL. Fungi, treated with compounds, were incubated at 
37 °C for 48 h to see the inhibitory effect of the compounds. The fungal MIC testing was 
done in triplicate trials. 
Procedure for kinetic cell permeabilization using 1×MIC of compounds. The 
fungi cell membrane permeabilization study was performed in a 96-well cell culture 
plate. C. neoformans H99 was grown in PDB medium at 37 °C for 48 h. From the 
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growth, 4 mL of fungi were taken and washed with water twice and resuspended in 1 mL 
of water. Fungi cells were counted, and cells were diluted to 4×106 Cells/mL as the final 
confluence. Then, compounds and dye were added to the fungi, maintaining the final 
concentration of compounds to 1×MIC, 0.01 µM for SYTOXTM green and 0.4 µg/mL for 
PI . The control cells were treated with dye only. The fluorescence intensity were 
measured in every 3 min for a period of four hours at 28 °C with an excitation/emission 
wavalength of 480Ex/525Em nm for SYTOXTM green and 537Ex/617Em nm for PI using the 
Cytation 5 imaging reader. The images of the compounds 7, 11, 13, and Triton X-100 
were taken after 60 min of incubation using the green channel and bright field filter set in 
the Cytation 5 imaging reader and Olympus IX 71.
Procedure for kinetic cell permeabilization using multiple MIC of the 
compounds.  This assay was performed silmilarly to the fungi cell membrane 
permeabilization study using 0.125×MIC to 8×MIC of compounds 2, 7, 10, and 11. The 
fluorescence intensity was measured every 3 min for a period of two or four hours. The 
images of the representative compound 11 were taken after the 60 min of incubation 
using the green channel for SYTOXTM green and after 120 min using the red channel for 
PI along with the bright field filter set.  
Procedure for reactive oxygen species (ROS) generation study. The effect of 
the amphiphilic kanamycin to generate ROS species in the fungal cells was studied in the 
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C. neoformans H99 strain, using the previously reported ROS generating amphiphilic
antifungal compound 14, as the positive control [25,26]. The fungal cells were grown in 
PDB medium at 28 °C  for 48 h with gentle shaking. The cells were washed with water 
twice before using for the assay by centrifugation at 10,000 rpm for 2 min. A volume of 
0.5 mL of cells in water (final cell confluence, 4×107 cells/mL) was incubated with 
1×MIC of the compounds for 3 h at 37  °C . Then, the cells were washed twice with 0.5 
mL water and finally resuspended in 0.5 mL water. The cells were then incubated for 
another 30 min with 2′,7′-dichlorodihydrofluorescein diacetate 
(DCF-DA) dye (25 mM final concentration) at 37  °C . After incubation, the cells were 
washed twice with the same volume of water and resuspended in water. The fluorescence 
of the cells was measured in the Cytation 5 imaging reader with an excitation and 
emission wavelength of 485 nm and 525 nm respectively. The experiment was performed 
at least in triplicate. 
2-4. Conclusions
We have examined the antifungal activities of 4″,6″-diaryl kanamycins a well as 
the previously described 4″,6″-dialkyl kanamycins. These two classes of AKs show 
similar antifungal profiles against a panel of fungi despite having different hydrophobic 
groups. The amphiphilicity parameter cLogD can be useful for the structural design when 
no obvious SAR can be deduced, Using the fluorogenic dye (SYTOXTM green), 4″,6″-
diaryl kanamycins were shown to exert their antifungal activities via increased plasma 
membrane permeability. It was shown, however, that the fluorescent properties of the 
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commonly used fluorogenic dyes SYTOXTM green and PI are drastically affected by the 
concentrations of the AKs. Therefore, to acquire meaningful results in such approaches, 
prudent practice is needed to establish the optimal ratio of AKs to fluorogenic dyes for 
the experiments. Finally, from a combination of studying kinetic membrane 
permeabilization, ROS production, cLogD and fungal growth MICs, we conclude that the 
mode of antifungal action of the 4″, 6″disubstituted AKs is a combination of plasma 
membrane permeabilization and oxidative stress. 
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CHAPTER 3 
INHIBITION OF CONNEXIN HEMICHANNELS BY NEW AMPHIPHILIC 
AMINOGLYCOSIDES WITHOUT ANTIBIOTIC ACTIVITY a 
3-1 Abstract
Connexins hemichannels (HCs) from adjacent cells form gap junctional channels 
that mediate cell-to-cell communication. Abnormal opening of “free” undocked HCs can 
produce cell damage and participate in the mechanism of disorders such as cardiac 
infarct, stroke, deafness, skin diseases, and cataracts. Therefore, inhibitors of connexin 
HCs have great pharmacological potential. Antibiotic aminoglycosides (AGs) have been 
recently identified as connexin HC inhibitors, but their antibiotic effect is an issue for the 
treatment of disorders where infections do not play a role. Herein, we synthesized and 
tested several amphiphilic AGs without antibiotic effect for their inhibition against 
connexin HCs, using a newly developed cell-based bacterial growth complementation 
assay. Several leads with superior potency than the parent compound, kanamycin A, were 
identified. Unlike traditional AGs, these amphiphilic AGs are not bactericidal and are not 
toxic to mammalian cells, making them better than traditional AGs as HC inhibitors for 
clinical use and other applications. 
a Adapted with permission from (AlFindee, M. N.; Subedi, Y. P.; Fiori, M. C.; Krishnan, S.; Kjellgren, A.; 
Altenberg, G. A.; Chang, C.-W. T. “Inhibition of Connexin Hemichannels by New Amphiphilic 
Aminoglycosides without Antibiotic Activity” ACS Med. Chem. Lett. 2018, 9, 697-701). Copyright © 
2018, American Chemical society 
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3-2 Introduction
Cell-to-cell communication is essential for transporting metabolites, ions, and 
signal molecules between adjacent cells. This occurs predominantly through gap-junction 
channels (GJCs) that are formed when two connexin hemichannels (HCs; connexin 
hexamers), one from the adjacent cells, dock head-to-head (Figure 3-1).1,2 There are 21 
connexin isoforms that form a variety of GJCs and HCs that differ in permeability and 
regulation.1−3 The importance of GJCs in physiology and pathophysiology is well 
established from several decades of research, but the role of plasma-membrane 
Figure 3-1. Schematic representation of a connexin monomer, a hemichannel (HC) and a 
gap-junction channel (GJC). Each cylinder in HC and GJC corresponds to a con-nexin 
subunit. 
undocked HCs is more recent.2,4,5 Most HCs are closed under normal conditions, but they 
still participate in autocrine and paracrine signaling through the efflux of ATP, NAD+, 
glutamate, prostaglandins, and other mediators.6 HCs also seem to play a role in disorders 
of the inner ear (deafness), eye (cataracts), heart (infarcts), and brain (cerebrovascular 
accidents).2,5 Abnormal opening of the “large” nonselective HCs can damage cells by 
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depolarization, swelling, alterations in ionic gradients, and concentrations of metabolites 
and second messengers. There is interest in the finding and development of connexin HC 
inhibitors since they could offer insights on the role of HCs in normal function and 
disease, as well as serve as therapeutics in disorders associated with connexin HCs. 
A variety of molecules have been investigated for their inhibitory effect toward 
connexin HCs, including 2-amino- ethoxydiphenyl borate, ioxynil, carbenoxolone, 18-β-
glycyrrhetinic acid, antimalarial drugs (mefloquine), and n-alkanols7 (Figure 3-2). These 
compounds cannot be used as starting points for the development of clinically useful HC 
inhibitors because they are not selective for connexin HCs and/or they are toxic.7 
Connexin peptide inhibitors are synthetic peptides corresponding to sequences of 
connexins’ extracellular or intracellular loops.7−9 Some of the peptide-based connexin  
Figure 3-2. Examples of inhibitors of connexin HCs. 
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inhibitors have been used to treat arrhythmias and to accelerate wound healing.7−9 Most 
of these peptides act on GJCs and HCs, but a few seem to selectively inhibit HCs.7 
However, their clinical potential is still unclear,10 and nevertheless, other avenues to 
develop clinically useful inhibitors for HC have been mostly unexplored. In this context, 
aminoglycosides (AGs) such as kanamycin and gentamicin have been recently identified 
as potent inhibitors of connexin HCs.11−14 AGs have been used as antibacterial agents for 
over 60 years, and they are still among the most used antibiotics.15,16 Although 
nephrotoxicity and ototoxicity are relatively common complications of AGs treatment, 
they can be managed.17 We have discovered that chemically modified AGs, especially 
amphiphilic kanamycin derivatives, have biological activity while showing significantly 
reduced cytotoxicity.18−23 With this in mind, we began to explore amphiphilic kanamycin 
derivatives as connexin HC inhibitors, using connexin 26 (Cx26) HCs as test targets.  
We have reported a three-step synthesis of amphiphilic kanamycin derivatives 
bearing linear alkyl chains at the O-4″, O-6″, or O-4″ and O-6″ positions of kanamycin A 
(Scheme 3-1).19 These derivatives show moderate antifungal activity and no antibacterial 
activity, making them good candidates as Cx26 HC inhibitors without antibiotic effect; 
they could be used without the risk of promoting the generation of AG-resistant bacteria. 
Five amphiphilic kanamycin A derivatives were selected randomly for testing. To 
provide more information in structure-activity relationship (SAR), we also synthesized 
three additional derivatives: one with a benzyl (Bn) group attached at O-4″and O-6″ 
positions (compound 7) and two with or without a Bn group attached at O-4″and O-6″ 
positions, and a methyl (Me) group at other hydroxyl groups (5, 2′, 3′, 4′, and 2″)  
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Scheme 3-1 
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(compounds 8 and 9, respectively). These derivatives were prepared by sequential 
benzylation and methylation followed by reduction of azido groups or hydrogenolysis of 
the Bn. To elucidate the role of amino groups, compound 1 (Scheme 3-1) was also tested. 
Please see the Appendix B for details on the synthesis and characterization of the new 
kanamycin derivatives, including the use of acetylation and 1H−1H COSY for the 
confirmation of the sites of modifications. 
Connexin HC inhibition was conducted using a bacteria-based assay of HC 
function.14 In this assay, Cx26 HCs are expressed in E. coli LB2003 cells, which lack 
three major K+ uptake systems (Kdp, Kup, and Trk), and as a result, they cannot grow in 
low-[K+] media.14,24,25 However, growth of this E. coli strain in low-[K+] medium can be 
rescued by expression of K+-permeable channels such as connexin HCs.13,14,26 Under the 
conditions of the assay (LB2003 cells expressing HCs and grown in low-K+ medium), 
inhibition of the HCs reduces or abolishes growth.13,14,26 This is a simple assay where 
bacterial growth in multi-well plates can be followed by measuring the absorbance at 600 
nm (OD600).14 Although not formally needed for most of the AGs tested here (they do not 
have antibiotic effect), we routinely transform the E. coli LB2003 with a plasmid that 
codes for the AG modifying enzyme aminoglycoside 3′-phosphotransferase, which makes 
the cells resistant to kanamycin A and its derivatives.14 
3-3 Results and Discussions
The kanamycin derivative without a free amino group (compound 1) was inactive, 
suggesting an essential role of this group. One of the disubstituted derivatives (compound 
3) displayed a lower IC50 for inhibition of growth dependent on Cx26 than the
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monosubstituted compound 4 (Table 3-1). Compared to compound 3 (hexyl), the potency 
was reduced when the alkyl chain length was shortened to butyl in compound 2 or 
extended to octyl (compound 5) or nonyl (compound 6). 
Table 3-1. Inhibition of Cx26-dependent cell growth by kanamycin A and synthetic AGs 
Compound Modifications IC50 (µM) 
Kanamycin A - 9.4 ± 1.1 
1 - No effect a 
2 butyl at O-4″ and O-6″ 19.0 ± 2.8 b 
3 hexyl at O-4″ and O-6″ 6.2 ± 1.4 
4 hexyl at O-4″ 13.5 ± 1.8 b 
5 octyl at O-4″ and O-6″ 13.6 ± 0.5 b 
6 nonyl at O-4″ and O-6″ 18.8 ± 1.3b 
7 Bn at O-4″ and O-6″ 7.6 ± 1.2 
8 Me at 5, 2′, 3′, 4′ and 2″, Bn at O-4″ 
and O-6″ 
8.4 ± 1.4 
9 Me at 5, 2′, 3′, 4′ and 2″ No effect a 
a No effect: the absence of inhibition at 100 μM. b Denotes P < 0.01 vs kanamycin A. 
The potency of compounds 7 and 8 was similar, implying that the presence of hydroxyl 
groups, or the associated hydrogen bond interactions, is not necessary for the AG effect 
on HCs. However, the lack of inhibitory activity of compound 9 demonstrates that having 
hydrophobic groups at O-4″ and/or O-6″ positions is essential in the absence of hydroxyl 
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groups (compare compounds 8 and 9). The maximal inhibition of growth dependent on 
Cx26 was similar to that of kanamycin A and was not statistically different among the 
new compounds with inhibitory effect (compounds 2−8), averaging 99 ± 3%. 
From the data in Table 3-1, compounds 3, 7, and 8 were the most potent 
inhibitors. However, derivatization based on the hexyl group scaffold of compound 3 is 
difficult. Because of the ease of the chemical synthesis and purification process, we 
decided to focus on the derivatization bearing aryl-based substituents. Compounds 7 and 
8, with Bn groups at O-4″ and O-6″, can be readily modified with variations of 
substituents on the benzene ring or shape/size of the aromatic motif. Considering the 
simpler reaction scheme and the flexibility on the groups accepted at the O-4″ and O-6″ 
positions, and in the absence of an advantage of compound 8 over compound 7, we 
selected the latter for further development.  
A library of kanamycin derivatives bearing arylmethyl substituents was 
synthesized to investigate two factors related to SAR (please see Appendix B), the 
electronic and steric (size) effects of the aryl group; see Scheme 3-2 and Table 3-2, and 
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Scheme 3-2 
an expanded table (Table B-1). We selected four benzene derivatives with electron-
donating and withdrawing substituents (methoxy, methyl, chloro, and fluoro) at the para 
position to explore the first factor. Three arylmethyl groups, 1-naphthalenemethyl, 2- 
naphthalenemethyl, and biphenyl, were selected for studying the second factor. The 
synthesis was conducted as described previously,19 using commercially available 
arylmethyl bromides. When alkylating compound 1, we observed a significant amount of  
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Table 3-2. Second generation synthetic AGs. 
Compound R IC50 (µM) 
10 13.0 ± 0.7** 
11 4.3 ± 0.4* 
12 2.5 ± 0.6** 
13 8.1 ± 0.5 
14 4.9 ± 0.2* 
15 
6.6 ± 0.5 
16 
6.2 ± 0.7 
* and ** denote P < 0.05 and P < 0.01 vs. compound 7, respectively.
monosubstituted adducts bearing arylmethyl groups at O-4″ or O-6″ positions. Attempts 
to improve the yields for disubstituted adducts by varying the equivalents of arylmethyl 
bromides or separating two monosubstituted adducts using flash chromatography were 
unsuccessful. Therefore, only the disubstituted adducts were isolated to proceed toward 
the completed synthesis. The IC50 values for inhibition by these derivatives are 
summarized in Table 3-2. It appears that the relationship between the electronic effect 
and inhibitory potency is not strong, but rather subtle. Compounds with a moderate 
electron-donating group (CH3-, compound 11) or moderate electron-withdrawing group 
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(Cl-, compound 12) showed better activities than those with a strong electron- donating 
(CH3O-) group (compound 10) or a strong electron- withdrawing (F) group (compound 
13). Compounds 11 and 12 had superior inhibitory potency than kanamycin A and the 
parent compound 7, which has no substituent on the benzene ring. The inhibitory potency 
of the derivative with a bicyclic aromatic ring (compound 14) was slightly higher than 
that of compounds 15 and 16, but the differences were not major. Combining these 
results, it seems that compounds 11, 12, and 14 can all serve as leads for further 
development. The maximal inhibition of growth dependent on Cx26 was similar for 
compounds 10−16 and averaged 94 ± 2%. Examples of growth inhibition by three of the 
new aminoglycosides, including compound 12, are shown (Figure B-1).  
All of the kanamycin derivatives were examined for their antibacterial activity 
against E. coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923). Except for 
compounds 15 and 16, which have minimum inhibitory concentrations (MICs) of 64 and 
16 μg/mL against S. aureus, respectively, the derivatives did not show significant 
antibacterial activity, with MICs ranging from 128 to >256 μg/mL against both bacteria. 
The cytotoxicity of the newly synthesized disubstituted kanamycin derivatives on HeLa 
cells was also examined and is presented in (Figure B-2).  Compounds 13, 14, and 16  
showed moderate cytotoxicity (40−60% reduction of cell viability) at 100 μg/mL, which 
is at least 20-fold higher than the corresponding IC50 for Cx26 HC inhibition. No 
significant reduction of cell viability was observed for the rest of the compounds at 
concentrations up to 100 μg/mL. The low cytotoxicity is advantageous for potential uses 
as therapeutics. 
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3-4 Conclusion
We have discovered a new application for amphiphilic kanamycin derivatives as 
connexin HC inhibitors. Previous studies have shown that the AG gentamicin inhibits 
HC, but not GJCs,12 although indirect GJC inhibition, probably through the generation of 
free radicals, has also been reported.27 Therefore, the issue of selective inhibition of HC 
vs. GJC by AGs remains to be clarified. In any case, the new amphiphilic kanamycin 
derivatives presented here represent a novel class of HC inhibitors that have the 
advantages of not having antibacterial activity and displaying low cytotoxicity. We have 
identified the preferred structural motifs for improving HC inhibitory potency. 
Development of suitable connexin HC inhibitors may pave the way for better 
understanding the mechanism of HC inhibition and the role of connexin HCs in human 
disorders. 
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CHAPTER 4 
ONE-STEP SYNTHESIS OF CARBOHYDRATE ESTERS AS ANTIBACTERIAL 
AND ANTIFUNGAL AGENTS a 
4-1 Abstract
 Carbohydrate esters are biodegradable, and the degraded adducts are naturally 
occurring carbohydrates and fatty acids which are environmentally friendly and non-toxic 
to human. A simple one-step regioselective acylation of mono-carbohydrates has been 
developed that leads to the synthesis of a wide range of carbohydrate esters. Screening of 
these acylated carbohydrates revealed that several compounds were active against a panel 
of bacteria and fungi, including Staphylococcus aureus, methicillin-resistant S. aureus 
(MRSA), Candida albicans, Cryptococcus neoformans, Aspergillus flavus, and Fusarium 
graminearum. Unlike prior studies on carbohydrate esters that focus only on antibacterial 
applications, our compounds are found to be active against both bacteria and fungi. 
Furthermore, the synthetic methodology is suitable for scale-up production for a variety 
of acylated carbohydrates. The identified lead compound, MAN014, can be used as an 
antimicrobial in applications such as food processing and preservation and for treatment 
of bacterial and fungal diseases in animals and plants. 
a Adapted with permission from (AlFindee, M. N.; Zhang, Q.; Subedi, Y. P.; Shrestha, J. P.; Kawasaki, Y.; 
Grilley, M.; Takemoto, J. Y.; Chang, C.-W. T. “One-Step Synthesis of Carbohydrate Esters as Antibacterial 
and Antifungal Agents” Bioorgan. Med. Chem. 2018, 26, 765–774). Copyright © 2018, Elsevier BV. 
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4-2 Introduction
Fungal and bacterial pathogens cause significant economic losses in agriculture and
food industry. For example, it is estimated that fungal pathogens destroy more than 125 
million tons/yr of the top five food crops (rice, wheat, maize, potatoes, and soybeans) that 
can feed more than 600 million people.3 Food recalls due to pathogen contamination or 
illness from foodborne diseases cause significant economic loss.4 Common disinfection 
practices in the food industry involve chemical disinfection and irradiation (e.g., X-ray).5-
6 While chemicals, such as hypochlorites, iodophors, peroxyacetic acid, and quaternary 
ammonium compounds, have longer lasting effectiveness than observed following 
irradiation,7 these chemicals pose health and environmental hazards to humans and 
animals.8 Recently, there is a trend of using natural products (e.g., tea) in combating 
foodborne bacterial and fungal pathogens,9-10 however, the antimicrobial activities of 
most natural products are too low to enable their practical use. In the area of food 
preservatives, sodium benzoate and maleic acid are two common food preservatives. 
Nonetheless, sodium benzoate may undergo decarboxylation when used with acidic 
components, (such as vitamin C), leading to the formation of carcinogenic benzene, and 
maleic acid interrupts the cell energy metabolism.11-12 Potassium sorbate is a popular 
natural food preservative that is generally regarded as safe (GRAS) by the FDA. 
Nevertheless, potassium sorbate has been reported to be toxic and mutagenic to human 
blood cells.13 In short, there is still a great need for useful natural antimicrobial food 
additives that are GRAS. 
Carbohydrate esters have attracted great interest due to their wide range of applications 
in industry and medicine.14-15 These compounds, mostly acylated at the primary hydroxyl 
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group, are biodegradable and non-toxic while they act as antimicrobials.16-17 
Carbohydrate esters are synthesized by two general methods: chemical and enzyme-
catalyzed synthesis.18 Both have advantages and disadvantages. Most of the syntheses of 
carbohydrate esters focus on enzyme-catalyzed esterification or transesterification. These 
latter methods have the advantage of selective incorporation of the acyl group at the 
primary hydroxyl group of carbohydrates without tedious protection and deprotection 
steps.19-21 However, this synthesis method has several drawbacks: First, the enzyme-
catalyzed reactions often employ chemically synthesized vinyl esters as the substrates or 
require the use of organic solvents.22-23 Therefore, the synthetic conditions are not 
amenable to “green” processes. Secondly, many enzymes, such as lipases, exert a 
significant degree of substrate specificity and the yields or conversion efficiency may 
vary drastically among different carbohydrates and fatty acids of various chain length.24 
Third, many of these reported reactions were conducted at mg to gram scale.25 The 
feasibility for scale-up production to kg scale remains to be demonstrated in most cases.  
 Chemical-based syntheses can generate a wide variety of carbohydrate esters 
without the limitation of substrate specificity. The regioselective chemical synthesis of 
carbohydrate esters is challenging. It is difficult to incorporate the acyl group selectively 
to the desired hydroxyl groups on carbohydrates. To circumvent this problem, many 
reported methods rely on multiple protection and deprotection steps to achieve the 
regioselective incorporation of the acyl group at the primary hydroxyl group of 
carbohydrates.26-28 This strategy not only increases the cost of synthesis but also reduces 
the prospects for green production processes and impedes the economical large scale 
production of carbohydrate esters. In short, the enzymatic process is regioselective but 
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can be challenging for scaled-up production while the chemical process is not region-
specific but is more suitable for making libraries of carbohydrate esters allowing a facile 
identification of leads.  
In light of the problems with traditional synthetic strategies of carbohydrate 
esters, our group began to explore a novel one-step chemical synthesis strategy for the 
regioselective production of carbohydrate esters. Our approach uses of the fact that most 
monosaccharides have one primary hydroxyl group which will be more reactive than 
secondary hydroxyl groups.29 By controlling the reaction condition, we promote 
regioselectively incorporation of the acyl group at the primary hydroxyl group similar to 
the enzymatic method. With this strategy, we gain easy access to diverse carbohydrate 
esters made from natural constituents, and that are subject to detailed structure-activity 
relationship (SAR) studies. The lead compounds can be quickly identified and then 
synthesized on a large scale. The lead carbohydrate esters can be purified to provide 
bioactive compounds consist of natural components. 
4-3 Materials and Methods
We selected four natural monosaccharides (mannose (1), glucose (2), N-
acetylglucosamine (3) and galactose (4)) and ten acyl groups (acetyl (C2), butanoyl (C4), 
hexanoyl (C6), octanoyl (C8), decanoyl (C10), dodecanoyl (C12), tridecanoly (C13), 
tetradecanoyl (C14), pentadecanoyl (C15), and hexadecanoyl (C16) for constructing 
libraries of carbohydrate esters. To accommodate the solubilities of the carbohydrates and 
acyl chlorides, pyridine was used as the solvent. The primary hydroxyl groups are more 
nucleophilic than the anomeric and the secondary hydroxyl groups. Therefore, the 
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regioselective acylation is expected to be achieved by controlling the equivalent of acyl 
chloride and the reaction temperature. In most of the cases, 1.5 equivalents of acyl 
chloride were employed to optimize the production of mono- over di-acylated 
carbohydrate esters. In some cases, 1.2 equivalents of the acyl chloride were used to 
obtain the monoacylated predominantly and 2.5 equivalents to yield predominantly the 
di-acylated products for comparison. All the reactions were conducted with 1-2 g of
carbohydrates and N,N-dimethylaminopyridine (DMAP) was used as the catalyst. 
Eight mannose esters with carbon chain from 2, 4, 6, 8, 10, 12, 14, and 16 were 
synthesized, and 1.5 eq. of acyl chloride was found to be optimal for generation of mono-
acylated mannose (Scheme 4-1). Despite numerous attempts, the mono-acylated  
Scheme 4-1. 
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mannose was obtained as an inseparable mixture of 6-O-acylated mannose and 2-O-
acylated mannose in 4:1 ratio (calculated from the 1H NMR and the sites of acylation 
were confirmed by the characteristic downfield shift of the diastereotopic H-6 protons as 
well as the coupling constant of H-2). Chemical derivatization of 6-O-acylated mannose 
and 2-O-acylated mannose using trityl chloride also failed to achieve the separation of 
these two regioisomers. Therefore, these mono-acylated mannose derivatives were tested 
for their biological activity as a mixture. Following the initial testing of biological 
activity, we found that the mannose ester with fourteen carbon chain (MAN014) was the 
most active against bacteria and fungi. To optimize the carbon chain length and provide 
more detailed SAR, we decided to expand our library to include methylmannopyranoside, 
5 with fourteen carbon chain ester (MM014) (Scheme 4-2). The 6-O-acylated adduct was 
obtained as the major product as expected. However, 3-O-acylated adduct was observed 
as the main by-product according to the integral ratio calculated from the 1H NMR. 
Scheme 4-2 
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For the same reason, mannose esters with acetyl (C2, MAN002), butanoyl (C4, 
MAN004), hexanoyl (C6, MAN006), tridecanoyl (C13, MAN013), and pentadecanoyl 
(C15, MAN015) groups were also prepared. A similar ratio of 6-O-acylated mannose and 
2-O-acylated mannose was observed for all the reactions.
Acylation of glucose with acyl chlorides of C8, C10, C12, and C14 was 
conducted in a similar fashion. The acylation of glucose is more regioselective than 
mannose. Five 6-acylated glucose derivatives, GLC008, GLC010, GLC012, GLC014, 
and GLC016 were synthesized, and site of acylation was confirmed again by the 
characteristic downfield shift of the diastereotopic H-6 protons (Scheme 4-3).30,20, 31-32 
Scheme 4-3 
Acylation of N-acetylglucosamine with acyl chlorides of C8, C10, C12, C14, and 
C16 was more challenging and offered a mixture of mono and diacetylated adducts 
(Scheme 4-4). To optimize the yields of both mono and diacetylated N-acetylglucosamine 
for biological study, we developed three different methods (Methods A, B, and C) for 
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their synthesis. Method A involves the use of 0.8 eq. of acyl chlorides to optimize the 
production of mono-acylated N-acetylglucosamine (NAG). In method C, 2.2 eq. of acyl 
chlorides were used to favor the production of di-acylated NAG. Finally, we discovered 
that using 1.5 eq. acyl chlorides (Method C) can generate mono- and di-acylated N-
acetylglucosamine (NAG) in one pot with satisfactory yields for both products, and these 
two products can be separated using column chromatography. The acylation took place at 
the O-6 position for the mono-acylated products. The sites of acylation for the 
diacetylated products occurred at O-6 and O-3. In all the cases the sites of acylation were 
confirmed by 1H and 1H-1H COSY NMR.  
Unfortunately, acylation of galactose provided a complex inseparable mixture with no 
distinct major products.  
Scheme 4-4 
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4-4 Results and Discussion
4-4.1 Antibacterial activity
All of the carbohydrate esters were tested against Gram-positive (G+) S. aureus 
(ATCC 25923) and Gram-negative (G-) Escherichia coli (ATCC 25922) using 
vancomycin, kanamycin A, neomycin as the controls. The minimum inhibitory 
concentrations (MICs) for these compounds are summarized in Table 4-1. MAN014 is 
the most active compound with MICs of 16 - 32 µg/mL and 128 µg/mL against S. aureus 
Table 4-1. MIC values of carbohydrate esters against bacteriaa
Entry Compound S. aureus
(ATCC
25923)
E. coli (ATCC
25922)
S. aureus (ATCC
33591) (MRSA)
1 MAN012 128 >256 128 - 256
2 MAN013 64 - 128 >256 ND 
3 MAN014 16 - 32 128 16 - 32 
4 MM014 128 >256 64 -128 
5 MAN015 64 >256 ND 
6 Vancomycin 2 >256 2 
7 Kanamycin 1 - 2 2 - 4 256 
8 Neomycin 2 2 - 4 >256
a Unit: (µg/mL), b ND: Not determined. 
and E. coli, respectively. MAN012, MAN014, and MM014 were chosen to be further 
tested against methicillin-resistant S. aureus (MRSA, ATCC 33591, and ATCC 43300), 
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Pseudomonas aeruginosa (G-, ATCC 27853), Klebsiella pneumoniae (G-, ATCC 13883). 
MAN014 is the most active compound against all of these bacterial strains with MICs of 
16 - 32 µg/mL and 128 µg/mL against MRSA and G- bacteria, respectively. Sodium 
myristate (C14) was tested, and no antibacterial activity was noted. Overall, the lead 
carbohydrate esters are more active against G+ than G- bacteria. In conclusion, MAN014 
has superior antibacterial activity than aminoglycosides (kanamycin and neomycin) 
against MRSA, and better activity against G- bacteria than vancomycin. 
4-4.2 Antifungal activity
A panel of human and plant fungal pathogens was used to test the antifungal 
activity for the synthesized compounds using voriconazole (an azole-class antifungal 
agent) and K2033 as controls (Table 4-2). In general, mannose esters, MAN015, 
MAN014, and MAN013 are relatively active against all the tested strains. Other  
Table 4-2. The MIC of carbohydrate esters against fungi a 
Entry 
Compound Aspergillusflavus 
Fusarium 
graminearum 
B4-5A 
Candida 
albicans 
64124 
(azole-
resistant) 
Candida 
albicans 
MYA2876 
(azole-
susceptible
) 
Cryptococcus 
neoformans 
H99 
Rhodotorula 
pilimanae 
1 MAN012 128 128 256 256 256 128 
2 MAN013 32 - 64 16 - 32 64 64 - 128 32 - 64 32 - 64 
3 MAN014 32 32 64 64 8 8 
4 MM014 > 256 4 - 16 > 256 > 256 256 > 256
5 MAN015 4 - 16 8 16 - 32 64 8 - 16 16
6 K20 > 256 8 256 64 4 4
7 Voriconazole 1 32 >256 0.125 0.125 8
a Unit: (µg/mL). 
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compounds have MIC values >256 µg/mL against the tested fungi. Candida albicans 
64124 is a human pathogen that is resistant to many clinically used azole-based 
antifungal agents. Aspergillus species are typically recalcitrant to most recognized 
antifungal drugs. Thus, infectious mycoses of humans and animals caused by pathogenic 
Aspergillus species are often untreatable and serious and have high mortality rates. It is 
noted that all three mannose esters are more active than the controls against C.  albicans 
64124 and Aspergillus flavus. Based on the results of antibacterial and antifungal 
activities, we conclude that mannose plays an essential role in the biological activity of 
carbohydrate esters. 
We have reported that amphiphilic antifungal kanamycin K20 can exert strong 
synergism with azole-based antifungal agents.34 Thus, we also conducted in vitro 
synergistic studies using MAN014 and several azole-class antifungal agents using the 
checkerboard method. The fractional inhibitory concentration index (FICI) is summarized 
in Table C-1. In contrast to K20 that shows strong synergism with most azoles, MAN014 
showed good synergy (FIC indices > 0.5) with all tested crop fungicides against A. flavus. 
On the other hand, MAN014 did not show synergy with all azoles tested against other 
fungal strains (table1 C-1). K20 is active against fungi but inactive against most bacteria 
while MAN014 displays a broad-spectrum activity against both fungi and bacteria.  
  
 
4-4.3 Mode of growth inhibitory action by MAN014  
 
              Carbohydrate esters are amphiphilic compounds and consequently are predicted 
to perturb cell membranes as their mode of action.35-37 Based on this assumption, 
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SYTOXTM  green dye was used to examine MAN014 effects on cell membrane 
permeability.38 Normally non-fluorescent, SYTOXTM  green becomes fluorescent when it 
enters cells through pores of permeable membranes and binds to nucleic acids. The 
capability of MAN014 to form membrane pores was tested with bacterial strain S. aureus 
(ATCC 25923) and the filamentous fungal strain, Fusarium graminearum B-4-5A using 
the protocols described by Weerden et al.36, 39 Strains were incubated with and without 
MAN014 for two hours.  Strains were incubated with MAN014 at 1×MIC, 2×MIC, and 
4×MIC.  MAN014 at 1×MIC caused increases of green fluorescence by SYTOXTM green 
in cells of both S. aureus (ATCC 25923) and F. graminearum B-4-5A (Figures 4-1 and 
4-2). Similar results were obtained with 2×MIC and 4×MIC of MAN014.  These 
observations support membrane pore formation as the mode of growth inhibitory action 
of MAN014 against bacteria and fungi. 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
 
 
Bright field Fluorescent 
  
  
Figure 4-1. S. aureus (ATCC25923) single hypha experiment, blank control (top row), 
and bacteria incubated with MAN014 at 1X MIC for 2h (bottom row). 
 
Bright field Fluorescent Merge 
 
Figure 4-2. Fusarium graminearum single hypha experiment, blank control (top row), 
and fungi incubated with MAN014 at 1X MIC for 2h (bottom row). 
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4-4.4 Mammalian cell cytotoxicity  
 A primary concern of using amphiphilic compounds in food, human, animal or 
other applications, is toxicity toward mammalian cells. The cytotoxicity of MAN014 was 
evaluated using three mammalian cells, including A549 (cancer epithelial lung), Beas-2B 
(normal, epithelial lung) and HeLa (adenocarcinoma, epithelial cervix), and MTT assay 
(Figure 4-3). The IC50 values for MAN014 were determined to be 107.65 ± 1.98, 77.35 ± 
6.14 and 71.76 ± 4.69 μg/mL for A549, Beas-2B, and HeLa, respectively. At low 
concentrations (up to 10 µg/mL), MAN014 appeared to have no cytotoxicity or even 
slightly promoted cell growth. Significant cytotoxicity of MAN014 was observed with a 
concentration at 100 μg/mL, which is 2-8 fold higher than the MICs.  
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Figure 4-3. Cytotoxicity of MAN014 
4-5 Large Scale Synthesis of MAN014
In an effort to demonstrate the feasible large-scale synthesis of lead compound. 
We carried out a 30g scale synthesis of MAN014 using 1.5 eq. myristoyl chloride. The 
reaction mixture was quenched by adding 1 N HCl and the products, which contained 
both mono- and di-acylated mannose was collected by filtration. Further purification 
using flash column chromatography provided MAN014 in 48% yield along with 28% of 
the di-acylated adduct. The purity of MAN014 was examined by 1H NMR, and no 
residual pyridine or DMAP can be observed. In contrast to the smaller scale synthesis, 
two types of di-acylated mannose derivatives were isolated as an inseparable mixture, 
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which consists of about 1/1 ratio of 2,6-di-O-acylated (α/β = 85/15, confirmed by gated 
13C NMR and COSY) and 1,3 di-O-acylated α/β = 60/40) adducts. These di-acylated 
products are difficult to assay for biological activity due to poor solubility in aqueous 
media.  
 
4-6 Conclusions 
We have successfully established a one-step synthesis of a library of carbohydrate 
esters. In contrast to most of the studies in this area that focus on antibacterial activity, 
several of the currently described synthesized carbohydrate esters are active against both 
fungi and bacteria. A detailed SAR was conducted allowing the identification of a lead 
compound, MAN014. MAN014 shows broad-spectrum activity against bacteria and 
fungi while having relatively low cytotoxicity toward animal cells. Mode of action 
studies confirms that MAN014 exerts its bioactivity via pore formation of the cell 
membrane. Finally, we have demonstrated that MAN014 can be synthesized in large 
scale with high purity. All of these features combined make MAN014 a prominent and 
environment-friendly antibacterial and antifungal natural compound that can be used for 
applications in medicine, public health, and agriculture. 
 
4-7 Experimental Section 
4-7.1 General Procedures. 
All chemicals were purchased from the commercially available resources without 
any further purification. Pyridine was dried over calcium hydride. Mass spectrometry was 
taken by high-resolution mass spectrometry (HRMS) using a TOF mass spectrometer at 
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University of California, Riverside mass spectrometry facility. Two NMR instruments 
were used JEOL300 (300 MHz) and Bruker Ascend (500 MHz) for the 1H and 75 or 125 
MHz for the 13C Nuclei. CDCl3 and CD3OD were used as solvents. The parts per million 
(ppm) were used to express the chemical shifts on the δ scale. The peaks splitting pattern 
were expressed as (s; for the singlet), (d; doublet), (t; triplet), (q; quadrate), (m; 
multiplet), and (ddd; doublet of doublets of doublets). Coupling constants J were 
measured in Herts (Hz). 
 
4-7.2 General procedure for the synthesis of acylated mannose and glucose. 
 
Synthesis of mono-acylated sugars, 0.5 g (1 equiv.) of sugar (glucose or mannose) 
and 1.5 equiv. of corresponding acyl chloride was stirred in 20 mL of pyridine for 
overnight. The formation of the product was confirmed by TLC (EtOAc/MeOH = 9/1). 
The reaction solution was concentrated under reduced pressure, and the crude oily 
reaction mixture was loaded to a silica gel column. The column chromatography was 
eluted by a gradient from pure EtOAc to EtOAc/MeOH = 9/1. After the column, the 
collected product was dried under reduced pressure to offer slight yellowish solid. The 
purity of the carbohydrates was confirmed by 1H NMR (the final product is mainly α 
sugar mixed with a small amount of β sugar due to the natural constitution of the 
corresponding sugar). 
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4-7.3 General procedure for the synthesis of acylated N-acetylglucosamine. 
 
Method A: 0.5 g (1 equiv.) of N-acetylglucosamine and 0.8 equiv. of corresponding 
acyl chloride was stirred in 20 mL of pyridine for overnight. The formation of the product 
was confirmed by TLC (Hexane: EtOAc = 7.5:2.5). The reaction solution was 
concentrated under reduced pressure, and the crude oily reaction mixture was loaded to a 
silica gel column. The column chromatography was eluted by a gradient from pure 
Hexans to Hexans: EtOAc = 7.5:2.5. After the column, the collected product was dried 
under reduced pressure to offer slight yellowish solid 
Method B: 0.5 g (1 equiv.) of N-acetylglucosamine and 2.2 equiv. of corresponding 
acyl chloride was stirred in 20 mL of pyridine for overnight. The formation of the product 
was confirmed by TLC (Hexans: EtOAc = 7.5:2.5). The reaction solution was 
concentrated under reduced pressure, and the crude oily reaction mixture was loaded to a 
silica gel column. The column chromatography was eluted by a gradient from pure 
Hexans to Hexans: EtOAc = 7.5:2.5. After the column, the collected product was dried 
under reduced pressure to offer slight yellowish solid. 
Method C: 0.5 g (1 equiv.) of N-acetylglucosamine and 1.5 equiv. of corresponding 
acyl chloride was stirred in 20 mL of pyridine for overnight. The formation of the product 
was confirmed by TLC (Hexane: EtOAc = 7.5:2.5). The reaction solution was 
concentrated under reduced pressure, and the crude oily reaction mixture was loaded to a 
silica gel column. The column chromatography was eluted by a gradient from pure 
Hexane to Hexane: EtOAc = 7.5:2.5. After the column, the collected product was dried 
under reduced pressure to offer slight yellowish solid.  
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4-7.4 6-O-Acetyl-D-mannopyranose (MAN002).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN002 was obtained as a light yellowish oil (0.27 g, 1.19 mmole, 43%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.06 (s, 1H), 4.38 (dd, J = 11.8 Hz, J = 2.0 Hz, 1H), 4.22 (dd, J = 11.9 Hz, J 
= 6.2 Hz, 1H), 3.6 – 4.0 (m, 4H), 2.07 (s, 3H); 13C NMR (CD3OD, 125 MHz) δ 171.61, 
94.51, 71.38, 70.78, 70.22, 67.43, 63.94, 19.37; ESI/APCI Calcd. for C8H13O6 [M - 
OH]+ : 205.0712; Measured m/z : 205.0718. 
 
4-7.5 6-O-Butanoyl-D-mannopyranose (MAN004).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN004 was obtained as a light yellowish oil (0.30 g, 1.19 mmole, 43%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 4.38 (dd, J = 11.8 Hz, J = 2.0 Hz, 1H), 4.22 (dd, J = 11.8 Hz, J = 6.2 Hz, 
1H), 3.6 – 4.0 (m, 4H), 2.34 (t, J = 7.3 Hz, 2H), 1.6 – 1.7 (m, 2H), 0.9 – 1.0 (m, 3H); 13C 
NMR (CD3OD, 125 MHz) δ 174.12, 94.84, 71.38, 70.80, 70.30, 67.46, 63.75, 35.48, 
18.00, 12.59; ESI/APCI Calcd. for C10H17O6 [M-OH]+ : 233.1025; Measured m/z : 
233.1023. 
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4-7.6 6-O-Hexanoyl-D-mannopyranose (MAN006).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN006 was obtained as a light yellowish oil (0.31 g, 1.11 mmole, 40%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.06 (s, 1H), 4.38 (dd, J = 11.8 Hz, J = 2.0 Hz, 1H), 4.22 (dd, J = 11.8 Hz, J 
= 6.2 Hz, 1H), 3.6 – 4.0 (m, 4H), 2.35 (t, J = 7.5 Hz, 2H), 1.6 – 1.78 (m, 2H), 1.3 – 1.4 
(m, 4H), 0.9 – 1.0 (m, 3H); 13C NMR (CD3OD, 125 MHz) δ 174.29, 94.49, 71.38, 70.80, 
70.30, 67.46, 63.78, 33.55, 31.04, 24.27, 21.99, 12.59; ESI/APCI Calcd. for C12H21O6 
[M - OH]+ : 261.1338; Measured m/z : 261.1360.  
 
4-7.7 6-O-Octanoyl-D-mannopyranose (MAN008). 
   
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN008 was obtained as a light yellowish oil (0.49 g, 1.61 mmole, 58%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.05 (s, 1H), 4.35 (dd,  J = 11.3 Hz, J = 2.0 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.4 
– 4.0 (m, 4H), 2.3 – 2.4 (m, 2H), 1.5 – 1.7 (m, 2H), 1.2 - 1.4 (m, 8H), 0.88 (t, J = 6.6 Hz, 
3H); 13C NMR (CD3OD, 125 MHz) δ 174.28, 94.49, 71.38, 70.81, 69.41, 67.47, 61.38, 
33.59, 31.48, 28.81, 28.71, 24.60, 22.28, 13.05; ESI/APCI Calcd. for C14H25O6 [M-
OH]+ : 289.1651; Measured m/z : 289.1680.  
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4-7.8 6-O-Decanoyl-D-mannopyranose (MAN010).  
 
 Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN010 was obtained as a light yellowish oil (0.23 g, 0.69 mmole, 25%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.03 (s, 1H), 4.35 (dd, J = 11.5 Hz, J = 2.0 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.4 – 
4.0 (m, 4H), 2.3 – 2.4 (m, 2H), 1.5 – 1.7 (m, 2H), 1.2 - 1.4 (m, 12H), 0.88 (t, J = 6.6 Hz, 
3H); 13C NMR (CD3OD, 125 MHz) δ 174.28, 94.49, 71.37, 70.81, 70.30, 67.77, 63.81, 
33.60, 31.67, 29.21, 29.06, 29.04, 28.87, 24.61, 22.35, 13.11; ESI/APCI Calcd. for 
C16H29O6 [M - OH]+ : 317.1964; Measured m/z : 317.1990. 
 
4-7.9 6-O-Dodecanoyl-D-mannopyranose (MAN012).  
 
This compound has been reported previously.40-41 Please refer to the general 
procedure for the synthesis of carbohydrates esters. MAN012 was obtained as light 
yellowish oil (0.40 g, 1.11 mmole, 40%) in a mixture of α/β anomers in a 3/1 ratio. The 
reported NMR is for the α anomer. 1H NMR (CD3OD, 300 MHz) δ 5.0 – 5.1 (m, 1H), 
4.35 (dd, J = 11.6 Hz, J = 2.0 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.4 – 4.0 (m, 4H), 2.3 – 2.4 (m, 
2H), 1.5 – 1.7 (m, 2H), 1.2 - 1.4 (m, 16H), 0.88 (t, J = 6.5 Hz, 3H). 
 
4-7.10 6-O-Tridecanoyl-D-mannopyranose (MAN013).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN013 was obtained as a light yellowish oil (0.23 g, 0.61 mmole, 24%) in a mixture of 
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α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.03 (s, 1H), 4.35 (dd,  J = 11.6 Hz, J = 2.0 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.4 
– 4.0 (m, 4H), 2.3 – 2.4 (m, 2H), 1.5 – 1.7 (m, 2H), 1.2 - 1.4 (m, 18H), 0.88 (t, J = 6.6 
Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 174.26, 94.51, 71.40, 70.81, 71.31, 67.47, 
63.78, 33.58, 31.68, 29.39 (2 Carbons), 29.36 (2 Carbons), 29.34, 29.22, 29.08, 28.85, 
22.33, 13.03; ESI/APCI Calcd. for C19H36O7Na [M + Na]+ : 399.2353; Measured m/z : 
399.2339. 
 
4-7.11 6-O-Tetradecanoyl-D-mannopyranose (MAN014).   
 
This compound has been reported previously.42 Please refer to the general 
procedure for synthesis of carbohydrates esters. MAN014 was obtained as a light 
yellowish solid (0.52 g, 1.33 mmole, 48%) in a mixture of α/β anomers in a 3/1 ratio. The 
reported NMR is for the α anomer. 1H NMR (CD3OD, 500 MHz) δ 5.03 (d, J = 1.6 Hz, 
1H), 4.39 (dd, J = 11.7 Hz, J = 2.0 Hz, 1H), 4.22 (dd, J = 11.7 Hz, J = 6.1 Hz, 1H), 3.7 – 
4.0 (m, 3H), 3.63 (t, J = 9.6 Hz, 1H), 2.35 (t, J = 7.5 Hz, 2H), 1.6 – 1.7 (m, 2H), 1.2 - 1.4 
(m, 20H), 0.91 (t, J = 6.9 Hz, 3H).  
 
4-7.12 2,6-Di-O-tetradecanoyl-D-mannopyranose (MAN014d). 
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN014d was obtained as a white solid: mp 88.7 - 94.6 °C (0.38 g, 0.63 mmole, 28%) 
in a mixture of α/β anomers in a 8.5/1.5 ratio. The reported NMR is for the α anomer. 1H 
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NMR (CDCl3, 500 MHz) δ 5.26 (s, H1), 5.17 (dd, J = 3.4 Hz, J = 1.6 Hz, H2), 4.57 (dd, 
J = 12.1 Hz, J = 4.1 Hz, H6eq), 4.29 (dd, J = 12.1 Hz, J = 2.1 Hz, H6ax), 4.11 (dd, J = 
9.5 Hz, J = 3.4 Hz, H3), 4.0 – 4.1 (m, H5), 3.64 (t, J = 9.7 Hz, H4), 3.4 – 4.0 (m, 4H), 
2.3 – 2.4 (m, 4H), 1.6 – 1.7 (m, 4H), 1.2 - 1.4 (m, 40H), 0.90 (t, J = 7.9 Hz, 6H); 13C 
NMR (CDCl3, 125 MHz) δ 174.86, 173.62, 93.78, 71.85, 70.71, 69.31, 67.85, 63.19, 
34.34, 34.24, 31.92 (2 Carbons), 29.69 (2 Carbons), 29.66 (7 Carbons), 29.61, 29.51, 
29.46, 29.36 (2 Carbons), 29.30, 29.28, 29.15, 29.10, 25.01, 24.93, 22.69 (2 Carbons); 
ESI/APCI Calcd. for C34H64O8Na [M + Na]+: 600.4601; Measured m/z : 623.4494. 
 
4-7.13 3,6-Di-O-tetradecanoyl-D-mannopyranose (MAN014d).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN014d was obtained as a white solid: mp 88.7 - 94.6 °C (0.38 g, 0.63 mmole, 28%) 
in a mixture of α/β anomers in a 6/4 ratio. The reported NMR is for the α anomer. 1H 
NMR (CDCl3, 500 MHz) δ 5.28 (s, H1), 5.21 (dd, J = 9.8 Hz, J = 3.1 Hz, H3), 4.57 (dd, 
J = 12.2 Hz, J = 4.5 Hz, H6eq), 4.37 (dd, J = 12.3 Hz, J = 2.2 Hz, H6ax), 4.0 – 4.1 (m, 
H2, H5), 3.87 (t, J = 9.8 Hz, H4), 3.4 – 4.0 (m, 4H), 2.3 – 2.4 (m, 4H), 1.6 – 1.7 (m, 4H), 
1.2 - 1.4 (m, 40H), 0.90 (t, J = 7.9 Hz, 6H); 13C NMR (CDCl3, 125 MHz) δ 174.86, 
173.62, 92.54, 71.17, 69.68, 68.85, 65.89, 63.14, 34.23, 34.17, 31.92 (2 Carbons), 29.69 
(2 Carbons), 29.66 (8 Carbons), 29.51, 29.45, 29.36 (2 Carbons), 29.30, 29.26, 29.20, 
29.10, 24.95, 24.87, 22.69 (2 Carbons); ESI/APCI Calcd. for C34H64O8Na [M + Na]+: 
600.4601; Measured m/z : 623.4494. 
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4-7.14 Methyl 6-O-tridecanoyl-α-D-mannopyranose (MM014).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MM014 was obtained as a light yellowish oil (0.58 g, 1.44 mmole, 52%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 4.62 (d,  J = 1.5 Hz, 1H), 4.42 (dd,  J = 11.7 Hz, J = 1.7 Hz, 1H), 4.22 (dd,  
J = 11.7 Hz, J = 6.6 Hz, 1H), 3.6 – 3.9 (m, 4H), 3.38 (s, 3H), 2.73 (t, J = 7.4 Hz, 2H), 
1.6 – 1.7 (m, 2H), 1.3 - 1.4 (m, 20H), 0.92 (t, J = 6.9 Hz, 3H); 13C NMR (CD3OD, 125 
MHz) δ 174.08, 101.38, 71.13, 70.63, 70.49, 67.30, 63.69, 53.81, 33.63, 31.69, 29.41, 
29.38 (2 Carbons), 29.35, 29.23, 29.10, 29.04, 28.84, 24.66, 22.35, 13.08; ESI/APCI 
Calcd. for C21H40O6 [M-OH]+ : 387.2747; Measured m/z : 387.2782. 
 
4-7.15 6-O-Pentadecanoyl-D-mannopyranose (MAN015).   
 
Please refer to the general procedure for synthesis of carbohydrates esters. 
MAN015 was obtained as a light yellowish oil (0.19 g, 0.47 mmole, 21%) in a mixture of 
α/β anomers in a 3/1 ratio. The reported NMR is for the α anomer. 1H NMR (CD3OD, 
500 MHz) δ 5.05 (d,  J = 1.75 Hz, 1H), 4.39 (dd,  J = 11.8 Hz, J = 2.0 Hz, 1H), 4.22 (dd,  
J = 11.8 Hz, J = 6.1 Hz, 1H), 3.7 – 4.0 (m, 3H), 3.6 – 3.7 (m, 1H), 2.3 – 2.4 (m, 2H), 1.6 
– 1.7 (m, 2H), 1.2 - 1.4 (m, 22H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (CD3OD, 125 MHz) 
δ 174.26, 94.51, 71.40, 70.80, 71.31, 67.47, 63.78, 33.58, 31.68, 29.39 (2 Carbons), 29.36 
(2 Carbons), 29.34, 29.22, 29.08 (2 Carbons), 28.85, 24.58, 22.33, 13.03; ESI/APCI 
Calcd. for C21H40O6Na [M + Na]+ : 427.2666; Measured m/z : 427.2652. 
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4-7.16 6-O-Hexadecanoyl-D-mannopyranose (MAN016).   
 
This compound has been reported previously.41 Please refer to the general 
procedure for the synthesis of carbohydrates esters. MAN016 was obtained as a light 
yellowish solid (0.53 g, 1.26 mmole, 56%) in a mixture of α/β anomers in a 3/1 ratio. The 
reported NMR is for the α anomer. 1H NMR (CD3OD, 300 MHz) δ 5.05 (s, 1H), 4.35 (dd,  
J = 11.7 Hz, J = 2.0 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.4 – 3.9 (m, 4H), 2.3 – 2.4 (m, 2H), 1.6 
– 1.7 (m, 2H), 1.2 - 1.4 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H).  
 
4-7.17 2-Acetamido-2-deoxy-6-O-octanoyl-α-D-glucopyranose (NAG008).   
 
Please refer to the method (A) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG008 was obtained as a light yellowish oil (0.44 g, 1.27 mmole, 
58%). 1H NMR (CD3OD, 500 MHz) δ 5.04 (d,  J = 3.4 Hz, 1H), 4.35 (dd,  J = 11.8 Hz, J 
= 2.0 Hz, 1H), 4.18 (dd,  J = 11.8 Hz, J = 5.1 Hz, 1H), 3.95 (ddd,  J = 9.9 Hz, J = 5.1 
Hz, , J = 2.0 Hz 1H), 3.83 (dd,  J = 10.6 Hz, J = 3.4 Hz, 1H), 3.67 (dd,  J = 10.6 Hz, J = 
8.9 Hz, 1H), 3.33 (dd,  J = 9.9 Hz, J = 8.9 Hz, 1H), 2.32 (t, J = 7.3 Hz, 2H), 1.96 (s, 3H), 
1.5 – 1.7 (m, 2H), 1.2 - 1.4 (m, 8H), 0.88 (t, J = 6.1 Hz, 3H); 13C NMR (CD3OD, 125 
MHz) δ 175.64, 173.79, 92.70, 72.64, 70.86, 70.01, 64.89, 55.94, 35.35, 32.99, 30.29, 
30.22, 26.15, 23.80, 22.76, 14.55; ESI/APCI Calcd. for C16H30NO7 [MH]+ : 348.2017; 
Measured m/z : 348.2025. 
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4-7.18 2-Acetamido-3,6-di-O-octanoyl-2-deoxy-α-D-glucopyranose (NAG008d).   
 
Please refer to the method (B) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG008d was obtained as a light yellowish solid: mp 111.9 – 116.5 
°C (0.51 g, 1.08 mmole, 48%). 1H NMR (CDCl3, 500 MHz) δ 6.37 (d,  J = 9.2 Hz, 1H), 
5.2 – 5.3 (m, 2H), 4.72 (d,  J = 3.4 Hz, 1H), 4.43 (dd,  J = 12.2 Hz, J = 3.6 Hz, 1H), 4.27 
(dd,  J = 12.0 Hz, J = 1.7 Hz, 1H), 4.0 - 4.2 (m, 2H), 3.5 – 3.6 (m, 1H), 3.24 (d,  J = 6.1 
Hz, 1H), 2.3 – 2.4 (m, 4H), 1.93 (s, 3H), 1.5 – 1.7 (m, 4H), 1.2 - 1.4 (m, 16H), 0.8 – 0.9 
(m, 6H); 13C NMR (CDCl3, 125 MHz) δ 175.55, 175.03, 170.91, 91.92, 73.17, 70.06, 
68.95, 63.04, 52.35, 34.53, 34.34, 31.84 (2 Carbons), 29.29 (2 Carbons), 29.20, 29.10, 
25.13, 25.06, 23.18, 22.78 (2 Carbons), 14.24 (2 Carbons); ESI/APCI Calcd. for 
C24H44NO8 [MH]+ : 474.3061; Measured m/z : 474.3081. 
 
4-7.19 2-Acetamido-2-deoxy-6-O-decanoyl-α-D-glucopyranose (NAG010).  
 
 Please refer to the method (C) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG010 was obtained as a light yellowish oil (0.21 g, 0.57 mmole, 
25%). 1H NMR (CD3OD, 500 MHz) δ 5.08 (d,  J = 3.4 Hz, 1H), 4.40 (dd,  J = 11.8 Hz, J 
= 2.1 Hz, 1H), 4.23 (dd,  J = 11.8 Hz, J = 5.3 Hz, 1H), 3.9 – 4.0 (m, 1H), 3.87 (dd,  J = 
10.7 Hz, J = 3.5 Hz, 1H), 3.72 (dd,  J = 10.6 Hz, J = 8.8 Hz, 1H), 3.38 (dd,  J = 9.9 Hz, 
J = 8.9 Hz, 1H), 2.36 (t, J = 7.5 Hz, 2H), 2.00 (s, 3H), 1.5 – 1.6 (m, 2H), 1.2 - 1.4 (m, 
12H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 174.14, 172.27, 91.19, 
71.15, 71.13, 69.35, 63.37, 54.44, 33.59, 31.63, 29.17, 29.01 (2 Carbons), 28.80, 24.62, 
22.31, 21.20, 13.02; ESI/APCI Calcd. for C18H34NO7 [MH]+ : 376.2330; Measured m/z : 
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376.2331. 
 
4-7.20 2-Acetamido-3,6-di-O-decanoyl-2-deoxy-α-D-glucopyranose (NAG010d).   
 
Please refer to the method (C) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG010d was obtained as a white solid: mp 107.1 – 115.9 °C (0.51 
g, 0.97 mmole, 43%). 1H NMR (CDCl3, 500 MHz) δ 6.37 (d,  J = 9.2 Hz, 1H), 5.2 – 5.3 
(m, 2H), 4.72 (d,  J = 3.4 Hz, 1H), 4.43 (dd,  J = 12.2 Hz, J = 3.6 Hz, 1H), 4.27 (dd,  J = 
12.0 Hz, J = 1.7 Hz, 1H), 4.0 - 4.2 (m, 2H), 3.5 – 3.6 (m, 1H), 3.24 (d,  J = 6.1 Hz, 1H), 
2.3 – 2.4 (m, 4H), 1.93 (s, 3H), 1.5 – 1.7 (m, 4H), 1.2 - 1.4 (m, 16H), 0.8 – 0.9 (m, 6H); 
13C NMR (CDCl3, 125 MHz) δ 175.55, 175.03, 170.91, 91.92, 73.17, 70.06, 68.95, 63.04, 
52.35, 34.53, 34.34, 31.84 (2 Carbons), 29.29 (2 Carbons), 29.20, 29.10, 25.13, 25.06, 
23.18, 22.78 (2 Carbons), 14.24 (2 Carbons); ESI/APCI Calcd. for C28H52NO8 [MH]+ : 
530.3687; Measured m/z : 530.3674. 
 
4-7.21 2-Acetamido-2-deoxy-6-O-dodecanoyl-α-D-glucopyranose (NAG012).   
 
Please refer to the method (C) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG012 was obtained as a white solid (0.26 g, 0.63 mmole, 28%). 
1H NMR (CD3OD, 500 MHz) δ 5.08 (d,  J = 3.5 Hz, 1H), 4.39 (dd,  J = 11.8 Hz, J = 2.0 
Hz, 1H), 4.22 (dd,  J = 11.8 Hz, J = 5.2 Hz, 1H), 3.9 – 4.0 (m, 1H), 3.86 (dd,  J = 10.6 
Hz, J = 3.4 Hz, 1H), 3.72 (dd,  J = 10.6 Hz, J = 8.9 Hz, 1H), 3.37 (dd,  J = 9.3 Hz, J = 
9.3 Hz, 1H), 2.35 (t, J = 7.5 Hz, 2H), 2.00 (s, 3H), 1.5 – 1.6 (m, 2H), 1.2 - 1.4 (m, 16H), 
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0.91 (t, J = 6.9 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 174.12, 172.26, 91.19, 71.15, 
71.13, 69.35, 63.37, 54.44, 33.59, 31.67, 29.33 (2 Carbons), 29.21, 29.06, 29.01, 28.81, 
24.62, 22.33, 21.21, 13.03; ESI/APCI Calcd. for C20H37NO7 [MH]+ : 403.2570; Measured 
m/z : 403.2649. 
 
4-7.22 2-Acetamido-3,6-di-O-dodecanoyl-2-deoxy-α-D-glucopyranose (NAG012d).   
 
Please refer to the method (C) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG012d was obtained as a white solid: mp 72.3 – 75.8 °C (0.51 g, 
0.97 mmole, 43%). 1H NMR (CDCl3, 500 MHz) δ 6.42 (d,  J = 9.2 Hz, 1H), 5.2 – 5.3 (m, 
2H), 4.44 (dd,  J = 12.2 Hz, J = 3.6 Hz, 1H), 4.32 (dd,  J = 12.1 Hz, J = 1.7 Hz, 1H), 4.1 
- 4.2 (m, 1H), 4.0 - 4.1 (m, 1H), 3.59 (d,  J = 9.4 Hz, 1H), 2.3 – 2.4 (m, 4H), 1.97 (s, 3H), 
1.5 – 1.7 (m, 4H), 1.2 - 1.4 (m, 32H), 0.88 (t, J = 6.9 Hz, 6H); 13C NMR (CDCl3, 125 
MHz) δ 175.35, 174.80, 170.86, 91.69, 72.97, 69.90, 68.78, 62.85, 52.23, 34.35, 34.15, 
31.90 (2 Carbons), 29.62 (2 Carbons), 29.61 (2 Carbons), 29.50 (2 Carbons), 29.33 (2 
Carbons), 29.29 (2 Carbons), 29.09, 29.06, 24.96, 24.88, 22.95, 22.67 (2 Carbons), 14.09 
(2 Carbons); ESI/APCI Calcd. for C32H60NO8 [MH]+: 586.4313; Measured m/z : 
586.4336. 
 
4-7.23 2-Acetamido-2-deoxy-6-O-tetradecanoyl-α-D-glucopyranose (NAG014).   
 
Please refer to the method (A) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG014 was obtained as a light yellowish solid: mp 149.1 – 153.2 
102 
 
 
 
°C (0.58 g, 1.33 mmole, 59%). 1H NMR (CD3OD, 500 MHz) δ 5.04 (d,  J = 3.4 Hz, 1H), 
4.37 (dd,  J = 11.8 Hz, J = 2.2 Hz, 1H), 4.20 (dd,  J = 11.7 Hz, J = 5.4 Hz, 1H), 3.9 – 4.0 
(m, 1H), 3.84 (dd,  J = 10.6 Hz, J = 3.4 Hz, 1H), 3.69 (dd,  J = 10.4 Hz, J = 8.7 Hz, 1H), 
3.35 (dd,  J = 9.6 Hz, J = 8.5 Hz, 1H), 2.36 (t, J = 7.3 Hz, 2H), 1.96 (s, 3H), 1.5 – 1.6 
(m, 2H), 1.2 - 1.4 (m, 20H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 
175.50, 175.02, 170.71, 92.01, 73.13, 70.20, 68.96, 63.03, 52.31, 34.55, 32.12, 29.86, 
29.71, 29.57, 29.50, 29.37, 29.31, 25.17, 25.10, 24.97, 23.28, 22.89, 14.32; ESI/APCI 
Calcd. for C22H42NO7 [MH]+ : 432.2956; Measured m/z : 432.2945. 
 
4-7.24 2-Acetamido-3,6-di-O-tetradecanoyl-2-deoxy-α-D-glucopyranose (NAG014d).   
 
Please refer to the method (B) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG014d was obtained as a light yellowish solid: mp 80.4 – 86.5 °C 
(1.17 g, 1.83 mmole, 81%). 1H NMR (CDCl3, 500 MHz) δ 6.23 (d,  J = 9.2 Hz, 1H), 5.2 
– 5.3 (m, 2H), 4.46 (dd,  J = 12.2 Hz, J = 3.6 Hz, 1H), 4.2 – 4.3 (m, 1H), 4.1 - 4.2 (m, 
1H), 4.0 - 4.1 (m, 1H), 3.58 (dd,  J = 9.6 Hz, 1H), 2.3 – 2.4 (m, 4H), 1.96 (s, 3H), 1.6 – 
1.7 (m, 4H), 1.2 - 1.4 (m, 40H), 0.86 (t, J = 6.7 Hz, 6H); 13C NMR (CDCl3, 125 MHz) δ 
175.68, 173.81, 92.01, 73.13, 72.20, 68.96, 63.03, 52.31, 34.55, 34.36, 32.12, 29.86 (8 
Carbons), 29.71 (2 Carbons), 29.57 (2 Carbons), 29.50 (2 Carbons), 29.37, 29.31, 25.17, 
25.10, 24.97, 23.28, 22.89 (2 Carbons), 14.32 (2 Carbons); ESI/APCI Calcd. for 
C36H68NO8 [MH]+ : 642.4939; Measured m/z : 642.4844. 
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4-7.25 2-Acetamido-2-deoxy-6-O-hexaadecanoyl-α-D-glucopyranose (NAG016).   
 
Please refer to the method (A) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG016 was obtained as a light yellowish solid: mp 124.8 – 129.4 
°C (0.59 g, 1.29 mmole, 57%). 1H NMR (CD3OD, 500 MHz) δ 5.08  (d,  J = 3.5 Hz, 1H), 
4.40 (dd,  J = 11.8 Hz, J = 2.0 Hz, 1H), 4.23 (dd,  J = 11.8 Hz, J = 5.3 Hz, 1H), 3.9 – 4.0 
(m, 1H), 3.87 (dd,  J = 10.6 Hz, J = 3.4 Hz, 1H), 3.72 (dd,  J = 10.5 Hz, J = 8.9 Hz, 1H), 
3.35 (dd,  J = 9.6 Hz, J = 8.5 Hz, 1H), 2.36 (t, J = 7.4 Hz, 2H), 2.00 (s, 3H), 1.5 – 1.6 
(m, 2H), 1.2 - 1.4 (m, 24H), 0.92 (t, J = 6.9 Hz, 3H); 13C NMR (CD3OD, 125 MHz) δ 
174.13, 172.26, 91.20, 71.15, 71.13, 69.35, 63.36, 54.44, 33.59, 31.67, 29.38 (3 Carbons), 
29.36 (2 Carbons), 29.33, 29.21, 29.07, 29.02, 28.82, 24.63, 22.33, 21.20, 13.03; 
ESI/APCI Calcd. for C24H46NO7 [MH]+ : 460.3269; Measured m/z : 460.3259. 
 
4-7.26 2-Acetamido-3,6-di-O-tetradecanoyl-2-deoxy-α-D-glucopyranose (NAG016d).   
 
Please refer to the method (B) for synthesis of mono and di-acylated N-
acetylglucosamine. NAG016d was obtained as a white solid: mp 101.4 – 109.5 °C (1.07 
g, 1.54 mmole, 68%). 1H NMR (CDCl3, 500 MHz) δ 5.88 (d,  J = 9.2 Hz, 1H), 5.2 – 5.3 
(m, 2H), 4.52 (dd,  J = 12.3 Hz, J = 3.7 Hz, 1H), 4.1 – 4.3 (m, 3H), 4.0 - 4.1 (m, 1H), 3.5 
– 3.6 (m, 1H), 3.11 (s, 1H), 2.82 (s, 1H), 2.3 – 2.4 (m, 4H), 1.94 (s, 3H), 1.6 – 1.7 (m, 
4H), 1.2 - 1.4 (m, 48H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR (CDCl3, 125 MHz) δ 175.15 
(2 Carbons), 174.71, 91.91, 72.85, 70.24, 68.70, 62.73, 52.11, 34.35, 34.16, 34.14, 31.93 
(2 Carbons), 29.71 (7 Carbons), 29.67 (5 Carbons), 29.63, 29.50, 29.37 (2 Carbons), 
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29.28, 29.17, 29.11, 25.00, 24.92, 23.17, 22.70 (2 Carbons), 14.13 (2 Carbons); 
ESI/APCI Calcd. for C40H76NO8 [MH]+ : 698.5565; Measured m/z : 698.5550. 
 
4-7.27 Antibacterial MIC Determination.  
A liquid culture of a selected bacterial strain was inoculated into Trypticase Soy 
broth at 35°C for 1-2 h. The bacteria cell concentration (no. of cells/mL and absorbance 
at 600 nm) was determined and diluted with broth, if necessary, to an absorbance value of 
0.08 to 0.1 at 600 nm. The adjusted inoculated medium (100 µL) was diluted with 10 mL 
of broth and then applied to a 96-well microtiter plate (50 µL). A series of solutions (50 
µL each in 2-fold dilution) of the tested compounds was added to the testing wells. The 
96-well plate was incubated at 35°C for 12 to18 h. The minimum inhibitory 
concentration (MIC) is defined as the minimum concentration of compound needed to 
completely inhibit the growth of bacteria. The MIC determinations for each experiment 
were repeated at least three times. 
 
4-7.28 Antifungal MIC and FIC Index Determinations. 
 
 In vitro growth inhibition of yeast strains by carbohydrate ester compounds were 
determined using MIC microbroth dilution assays in 96-well uncoated polystyrene 
microtiter plates (Corning Costar, Corning, NY, USA) as described in the M27-A2 
reference methods of the Clinical and Laboratory Standards Institute (CLSI) (formerly 
the National Committee for Clinical Standards Laboratory Standards) (NCCLS).43 Serial 
dilutions of compounds were made in uncoated polystyrene 96-well plates in the range of 
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0.25 to 512 μg/mL. For MIC determinations with filamentous fungi, previously described 
methods were used.44 FIC index determinations were carried out according to previously 
described methods by checkerboard analysis.45 Viable yeast cell or fungal spore 
concentrations were determined by agar medium plate colony counting.  The final 
concentration was adjusted to 1 × 105 colony forming units/mL.  The range of 
concentrations of drugs used for FIC index determinations was based on their 
corresponding MIC values.  Fungal growth was examined visually.  All experiments were 
done in duplicate. 
 
4-7.29 Cytotoxicity assay: 
Mammalian cells were grown in DMEM 1X (Gibco) supplemented with 10% 
fetal bovine serum (Gibco), 100 μg/mL streptomycin, and 100 U/mL penicillin.  Two-
hundred μL of cells (25,000 cells/mL) were added to 96-well cell culture treated plates 
(CorningTM) and incubated for 24 h at 37 °C with 5% CO2. Different concentrations of 
MAN014 (1.0, 10.0, 100.0 µg/mL) were added and incubated for another 48 h. Triton 
X100 was added to a separate well as a positive control.  For cell viability assay, 20 μL of 
MTT stock solution (5 mg/mL) was added to each well and incubated for 4 h. Upon 
completion of incubation, the media was carefully removed and washed twice with 100 
mL of PBS buffer. The live cells will reduce MTT reagent to purple crystals, which was 
dissolved in 200 μL of DMSO. Then the absorbance was measured at 570 nm and 670 
nm with a microplate reader (Synergy H4). The results are expressed as percentage 
viability compared with that of control.  For each type of mammalian cell, the assay was 
repeated 3 times, and each assay was performed in triplicate. The standard deviation was 
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determined from data sets of three independent experiments. 
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
Two libraries of amphiphilic compounds were successfully synthesized, and their 
bioactivities were tested. The first reported library of compounds was aryl substituted 
kanamycin A analogs for a detailed structure activity relationship study. This library was 
prepared using a novel three products protocol, and it was tested in two different 
applications: as antifungal agents and as connexin Cx26 inhibitors. 
Compounds 4 – 8 were able to strongly inhibit Fusarium graminraum B4-5A, 
Rhodotorula Pilimanae, Cryptococcus neoformans H99, and Cryptococcus neoformans 
VR-54 fungal growth with MIC rang 2-32 µg/mL. Most of the aryl substituted 
kanamycins did not have fungal growth inhibition against Candida albicans strains 
64124 and MYA2876 except compounds 4 and 6, which had good fungal growth with 
MIC = 32- 64 µg/mL. The mode of action study showed that these compounds might 
affect the cell membrane integrity. 
The aryl substituted kanamycins displayed low cytotoxicity toward mammalian 
cells except compounds 13, 14, and 16, which had moderate cytotoxicity at 100 µg/mL 
with 40 – 60 % reduced cell viability. Although compounds 13, 14, and 16 had moderate 
cytotoxicity, these compounds had at least 20-fold IC50 higher than the connexin Cx26 
inhibition counterpart. 
The aryl substituted kanamycins showed excellent connexin Cx26 inhibition 
behavior. Compounds 11, 12, and 14 were the most active (i.e., IC50 = 4.3, 2.5, and 4.9 
µM respectively) while compound 1 did not have any connexin inhibition up to 100 µM. 
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A library of aryl substituted kanamycins was synthesized and successfully 
repurposed in two applications: as antifungal agents and connexin inhibitors. Most of the 
compounds showed very good antifungal activity as well as strong connexin inhibition 
effect compares with kanamycin A (the parent compound). Finally, these compounds had 
low toxicity toward mammalian cells.  
The future directions for the antifungal agents are to study the nature of the dye 
compound interaction that diminished the fluorescence intensity when the compound 
concentration goes more than 2-fold of the MIC. This study will be done through 1) 
measuring the critical micelle concentration (CMC); 2) doing the same study with the 
compound being in neutral form. The future directions for aryl substituted kanamycins as 
connexin inhibitors are to further study the inhibition of these compounds against more 
connexin types that exist in the inner ear to see the selectivity of the amphiphilic 
kanamycins.  
The second reported class of compounds was carbohydrate esters. A simple and 
regioselective one step carbohydrate esterification protocol was successfully developed. 
This protocol was applied to build the library from three monosaccharides (glucose, 
mannose, and N-acetylglucosamine), and various acyl carbon chain lengths [ acetyl (C2) 
up to hexadecanoyl (C16)] to be studied in detailed structure activity relationship (SAR) 
study.  
The carbohydrate ester compounds were tested as antibacterial and antifungal 
agents against a panel of bacteria (Staphylococcus aureus, methicillin-resistant S. aureus 
MRSA, and Escherichia coli) and fungi (i.e., Aspergillus flavus, Fusarium graminraum 
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B4-5A, Candida albicans 64124, Candida albicans MYA2876, Cryptococcus 
neoformans, and Rhodotorula pilimanae). The SAR study identified the compound 
MAN014, mannose acylated with tetradecanoyl, as the lead with wide-spectrum 
antibacterial and antifungal activities with MIC rang 16 – 128 µg/mL against bacteria and 
4 – 64 µg/mL against fungi. 
Carbohydrate esters are biodegradable that decompose to a saccharide and a fatty 
acid, which are non-toxic. MAN014 showed low toxicity toward mammalian cells. This 
compound’s mode of action was through affecting the cell membrane integrity. Finally, 
MAN014 can be produced on large scales (i.e., 100g). These features all together, made 
environment friendly MAN014 an excellent candidate to be used as antimicrobial in 
medicine and agriculture. 
MAN014 was obtained as a mixture of two mono-acylated mannose at the 6 and the 
3 positions. The future directions for this project are to separate these two products and 
test their antibacterial, antifungal activities, and cytotoxicity. This will tell whether there 
is one active compound and the other is less active, or they act in synergistic manner. In 
addition to that, development of a green synthesis routes should be pursued.  
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Figure A-1. Kinetic Membrane Permeabilization of C. neoformans treated with: (A) AKs 
attached with aryl groups and Sytox; (B) AKs attached with aryl groups and PI; (C) AKs 
attached with alkyl groups and SYTOXTM green; (D) AKs attached with alkyl groups and 
PI. 
 
0 1 2 3 4
2
4
RF
U 
(X
 1
00
0)
Time (hr)
 Compd 8
 Compd 7 
 Compd 6
 Compd 5 
 Compd 4
 Compd 2
 Compd 3
 Compd 1
 Triton X-100
 Control
0 1 2 3 4
1
2
RF
U 
(X
 1
00
0)
Time (hr)
 Compd 8
 Compd 7 
 Compd 6
 Compd 5 
 Triton X-100
 Control
 Compd 4
 Compd 2
 Compd 3
 Compd 1
0 1 2 3 4
2
4
6
RF
U 
(X
 1
00
0)
Time (hr)
 Compd 9 
 Compd 10 
 Compd 12
 Compd 11
 Triton X-100
 Control
 Compd 13
0 1 2 3 4
0
2
4
RF
U 
(X
 1
00
0)
Time (hr)
 Compd 9 
 Compd 10 
 Compd 12
 Compd 11
 Triton X-100
 Control
 Compd 13
(A) (B) 
(C) (D) 
118 
 
 
 
 
0 1 2 3 4
2
4
Compound 7
RF
U 
(X
 1
00
0)
Time (hr)
 1XMIC
 0.5XMIC
 2XMIC
 Triton X-100
 4XMIC
 8XMIC
 Control
 
0 1 2
0
2
4
Compound 7
RF
U 
(X
 1
00
0)
Time (hr)
 1XMIC
 0.5XMIC
 2XMIC
 Triton X-100
 Control
 4XMIC
 8XMIC
 
 
0 1 2 3 4
2
4
RF
U 
(X
 1
00
0)
Time (hr)
 1XMIC
 0.5XMIC
 2XMIC
 Control
 4XMIC
 Triton X-100
 8XMIC
Compound 10
 
 
0 1 2
2
4
Compound 10
RF
U 
(X
 1
00
0)
Time (hr)
 2XMIC
 1XMIC
 0.5XMIC
 4XMIC
 Triton X-100
 Control
 8XMIC
 
 
0 1 2 3 4
2
4
Compound 11
RF
U 
(X
 1
00
0)
Time (hr)
 0.5XMIC
 1XMIC
 Control
 2XMIC
 Triton X-100
 4XMIC
 8XMIC
 
 
0 1 2
1
2
3
4
Compound 11
RF
U 
(X
 1
00
0)
Time (hr)
 1XMIC
 0.5XMIC
 2XMIC
 Triton X-100
 Control
 4XMIC
 8XMIC
 
Figure A-2. Kinetic membrane permeabilization of C. neoformans treated with multiple MIC of 
(A) 2 and 0.01 μM SYTOXTM green; (B) 7 and 0.01 μM SYTOXTM green; (C) 7 and 0.4 
(A) 
(B) 
(C) (D) 
(E) (F) 
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μg/mL PI; (D) ) 10 and 0.01 μM SYTOXTM green; (E) 10 and 0.4 μg/mL PI; (F) 11 and 
0.01 μM SYTOXTM green; (G) 11 and 0.4 μg/mL PI. 
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B-1. Materials and Methods 
Materials and Instrumentation 
Chemicals were used directly from commercial sources without further 
purification. DMF was dried over molecular sieves (Fisher scientific, Grade 514). 1H 
NMR, 13C NMR, and 1H-1H COSY spectra were acquired using JEOL300 (300 MHz) 
and Bruker Ascend (500 MHz) spectrometers at room temperature. A Shimadzu 
Prominence-i 2030C 3D LC system with an Agilent Zorbax RX-C18 5 μm 4.6 X 250 mm 
column was used for HPLC analysis of the compounds to confirm their purity. 
 
Biological Experiments 
Antibacterial assay: The minimum inhibitory concentration (MIC) of the newly 
synthesized compounds were tested against E. coli (ATCC 25922) and Staphylococcus 
aureus (ATCC25923). The concentration of bacteria grown in Lysogeny Broth (LB) was 
adjusted to an absorbance at 600 nm (OD600) of 0.08-0.1 using LB. A series of 2-fold 
dilutions was made for each compound in 96-well plates (USA Scientific CC7682-7596) 
starting from 256 µg/mL, and then, 50 µL of the diluted bacteria suspension was 
transferred to the wells. Bacteria were incubated for 18-24 h at 35˚C before measuring 
OD600 to assess growth. Experiments for each compound were done at least in duplicates. 
 
Connexin inhibition assay: We have found recently that functional human Cx26 HCs 
can be expressed in E. coli, and have developed and optimized a growth-
complementation assay to assess HC function using LB2003 as host1,2. LB2003 cells 
generously provided by Dr. E.P. Bakker (Osnabrük University, Osnabrük, Germany) 
were transformed with the plasmid pQE-Cx26 (human Cx26 into pQE60) and pREP4. 
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The plasmid pQE60 confers resistance to ampicillin, and pREP4 confers resistance to 
kanamycin and its derivatives. LB2003 cells cannot grow in low-[K+] media because of 
insufficient K+ uptake for growth due to the knockout of three key K+ transporters (Δtrk, 
Δkup, Δkdp strain)2-4. Details and validation of the growth complementation assay have 
been published recently2. In brief, competent LB2003 containing the pREP4 plasmid 
were transformed with pQE-Cx26. These cells were grown overnight in Luria- Bertani 
medium (BD, Franklin Lakes, NJ, USA) supplemented with 100 mM KCl (to allow 
growth) and 0.4 mg/mL ampicillin, and then washed four times with  NLM  (see  below),  
to remove residual K+ from the Luria-Bertani medium. The washed cells were 
resuspended in complementation growth medium to an OD600 of 0.2. NLM contained 46 
mM Na2HPO4, 23 mM NaH2PO4, 8 mM (NH4)2SO4, 0.4 mM MgSO4, 0.012 mM FeSO4, 
1 mM sodium citrate, 44 mM glucose and 0.006 mM thiamine hydrochloride, pH 7.0. 
KLM had the same composition that NLM except for the equimolar replacement of Na+ 
with K+.  For growth complementation we used NLM + 4 mM KCl, and Cx26 expression 
was induced with 0.5 mM IPTG at the time of dilution to OD600 = 0.2. For the assay, the 
cells were seeded in 96-well plates and were incubated at 30°C, with shaking at 500 rpm. 
OD600 was measured after 18-h incubation in a plate reader. The initial OD600 = 0.2 was 
subtracted for growth calculations. Data are presented as means ± SEM. Statistically 
significant differences were calculated by the Student t-test for unpaired data. Data were 
obtained from at least 3 independent experiments, with 3 repeats per experiment. 
 
Cytotoxicity assay: Cytotoxicity assays in HeLa cells were performed as described.5 
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Chemical Experiments 
 
General procedure for O-Alkylation of 1,3,6′,3″-tetraazidokanamycin A. 0.5 g of 
tetraazidokanamycin A was dissolved in 20 mL of dry DMF and a catalytic amount of 
tetrabutylammonium iodide (TBAI) was added. Then, 10 equivalents of NaH were added 
and the mixture was stirred for 15 min. After that, 1.5 equivalents of arylmethyl bromide 
was added and the reaction mixture was stirred overnight at room temperature. TLC 
(100% ethyl acetate elution) was used to confirm the completion of the reaction. The 
reaction was quenched by adding 5 mL of methanol, and the reaction mixture was 
concentrated and subjected to column chromatography (30:70 ethyl acetate: hexanes to 
0:100). Three yellowish sticky oil products were identified, but unfortunately two of them 
were in an inseparable mixture. 
 
General procedure for acetylation. 8 equivalents of Ac2O and 16 equivalents of Et3N 
were added to 0.02 g of the 4″,6″-Di-O alkylated tetraazidokanamycin dissolved in 20 
mL of anhydrous DCM, along with a catalytic amount of DMAP. The reaction mixture 
was stirred overnight at room temperature. After completion of the reaction, monitored 
by TLC, solvent was removed by compressed air. The residue obtained was purified by 
flash column using 100% DCM. This procedure is employed to allow 1H-1H COSY ex- 
periments to confirm the sites of alkylation6. The acylated adducts are not included in the 
manuscript but can be found in this document. 
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General procedure for Staudinger reaction and preparation of final compounds. 
Azide groups in alkyl substituted tetraazidokanamycin were reduced to amine by 
Staudinger reaction6. 
 
 
 
Figure B-1. Examples of inhibition of Cx26-dependent growth complementation by three 
of the new amphiphilic AGs. Each symbol corresponds to a triplicate average, and each 
color corresponds to an independent experiment. The lines are the fits of the Hill’s 
equation to the data. Growth inhibition was significant for the three compounds (P < 0.01 
vs. growth in the absence of drug). 
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Figure B-2. Cytotoxicity of kanamycin A and amphiphilic kanamycin derivatives. 
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Table B-1. Yields of second generation synthetic AGs. 
Compound Yield (%) Compound Yield (%) 
7b 32 10 54 
7c 35 11 88 
7d 41 12 58 
7e 37 13 71 
7f 41 14 72 
7g 43 15 42 
7h 26 16 74 
 
 
 
 
B-2 Compound Characterization Data 
 
 
4″,6″-Di-O-benzyl-1,3,6′,3″-tetraazidokanamycin (7a). 1H NMR (300 MHz, 
Methanol-D3) δ 7.2 – 7.4 (m, 10H), 5.21 (d, J = 3.9 Hz, 1H), 5.20 (d, J = 4.2 Hz, 1H), 
4.73 (d, J = 10.8 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 10.8 Hz, 1H), 4.44 (d, J 
= 12.0 Hz, 1H), 4.2 – 4.3 (m, 1H), 4.0 – 4.1 (m, 1H), 3.3 - 3.7 (m, 15H), 2.3 - 2.4 (m, 
1H), 1.52 (ddd, J = 12.3 Hz 1H). 13C NMR (75. MHz, Methanol-D3) δ 138.18 
(2 Carbons), 128.24 (2 Carbons), 128.11 (2 Carbons), 128.03 (2 Carbons), 127.97 (2 
Carbons), 127.60 (2 Carbons), 101.20, 98.43, 83.89, 80.05, 76.50 (2 Carbons), 74.39, 
73.54, 73.18, 72.63, 72.23, 71.22, 70.81, 70.26, 68.35, 66.92, 61.09, 59.61, 51.49, 32.18.  
ESI/APCI calcd for C32H40N12O11Na [M+Na]+ m/z 791.2832; measured m/z 791.2858. 
Yield: 196 mg (255mmol, 30%). 
 
 
127 
 
 
 
4″,6″-Di-O-(4-methoxybenzyl)-1,3,6′,3″-tetraazidokanamycin (7b). 1H NMR (500 
MHz, Methanol- D3) δ 7.28 (d, J = 7.7 Hz, 2H), 7.11 (d, J = 7.7 Hz, 2H), 6.89 (d, J = 7.4 
Hz, 2H), 6.85 (d, J = 7.4 Hz, 2H), 5.24 (d, J = 3.8 Hz, 1H), 5.23 (d, J = 3.5 Hz, 1H), 4.65 
(d, J = 10.4 Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.3 – 4.4 (m, 3H), 4.0 – 4.1 (m, 1H), 3.3 - 
3.7 (m, 21H), 2.3 - 2.4 (m, 1H), 1.55 (ddd, J = 12.5 Hz 1H). 13C NMR (125 MHz, 
Methanol-D3) δ 159.56, 159.49, 129.97, 129.81, 129.66 (2 Carbons), 129.52 (2 Carbons), 
113.46 (2 Carbons), 113.25 (2 Carbons), 101.00, 98.23, 83.67, 79.95, 75.94, 74.19, 73.88, 
73.37, 72.59, 72.45, 72.04, 70.96, 70.64, 70.05, 67.58, 66.72, 60.86, 59.44, 54.29, 54.27, 
51.32, 31.99. ESI/APCI calcd for C34H44N12O13Na [M+Na]+: 851.3048 m/z ; measured 
851.3096 m/z. Yield: 225 mg (272mmol, 32%). 
 
4″,6″-Di-O-(4-methylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7c). 1H NMR (300 
MHz, Methanol-D3) δ 7.0 – 7.2 (m, 8H), 5.20 (d, J = 2.7 Hz, 1H), 5.19 (d, J = 3.6 Hz, 
1H), 4.65 (d, J = 10.8 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H), 4.2 – 4.4 (m, 3H), 4.0 – 4.1 (m, 
1H), 3.3 - 3.7 (m, 15H), 2.3 - 2.4 (m, 7H), 1.52 (ddd, J = 12.3 Hz 1H). 13C NMR (75 
MHz, Methanol-D3) δ 137.42, 137.30, 134.96, 134.85 128.75 (2 Carbons), 128.56 (2 
Carbons), 128.17 (2 Carbons), 128.03 (2 Carbons), 101.07, 98.43, 83.76, 79.92, 76.15, 
74.24, 74.16, 73.41, 72.87, 72.50, 72.11, 71.05, 70.67, 70.08, 66.79, 60.96, 59.49, 51.37, 
32.08, 29.43, 19.92 (2 Carbons). ESI/APCI calcd for C34H44N12O11Na [M+Na]+: m/z 
819.3145; measured m/z 819.3158. Yield: 237 mg (298 mmol, 35%). 
 
4″,6″-Di-O-(4-chlorobenzyl)-1,3,6′,3″-tetraazidokanamycin (7d). 1H NMR (500 
MHz, Methanol-D3) δ 7.3 – 7.4 (m, 6H), 7.2 (d, J = 7.8 Hz 2H), 5.24 (d, J = 3.4 Hz, 2H), 
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4.76 (d, J = 11.3 Hz, 1H), 4.58 (d, J = 12.1 Hz, 1H), 4.51 (d, J = 11.1 Hz, 1H), 4.46 (d, J 
= 12.2 Hz, 1H), 4.3 – 4.4 (m, 1H), 4.0 – 4.1 (m, 1H), 3.3 - 3.7 (m, 15H), 2.3 - 2.4 (m, 
1H), 1.56 (ddd, J = 12.2 Hz 1H). 13C NMR (125 MHz, Methanol-D3) δ 138.87, 138.855, 
133.16, 133.11, 129.30 (2 Carbons), 129.09 (2 Carbons), 128.14 (2 Carbons), 128.01(2 
Carbons), 100.98, 98.24, 83.68, 79.90, 76.36, 74.21, 73.35, 73.19, 72.45, 72.05, 72.02, 
71.08, 70.64, 69.99, 69.18, 66.64, 60.91, 59.43, 51.31, 32.01. ESI/APCI calcd for 
C32H38Cl2N12O11Na [M+Na]+: 859.2058 m/z ; measured 859.2072 m/z. Yield: 292 mg 
(349 mmol, 41%). 
 
4″,6″-Di-O-(4-flurobenzyl)-1,3,6′,3″-tetraazidokanamycin (7e). 1H NMR (300 MHz, 
Methanol-D3) δ 7.2 – 7.4 (m, 4H), 6.9 – 7.1 (m, 4H), 5.25 (d, J = 3.6 Hz, 2H), 4.71 (d, J 
= 11.1 Hz, 1H), 4.53 (d, J = 11.4 Hz, 1H), 4.4 – 4.5 (m, 2H), 4.3 – 4.4 (m, 1H), 4.0 – 4.1 
(m, 1H), 3.3 - 3.7 (m, 15H), 2.3 - 2.4 (m, 1H), 1.52 (ddd, J = 12.3 Hz 1H). 13C NMR (75 
MHz, Methanol-D3) δ 162.50 (d, JCF = 243.1 Hz), 162.46 (d, JCF = 244.2 Hz), 134.12 (d, 
JCF  = 3.0 Hz), 134.07 (d, JCF  = 3.0 Hz), 129.77 (d, JCF  = 8.1 Hz, 2 Carbons), 129.65 (d, 
JCF = 8.2 Hz, 2 Carbons), 114.72 (d, JCF = 17.6 Hz, 2 Carbons), 114.55 (d, JCF = 17.6 
Hz, 2 Carbons), 101.06, 98.31, 83.74, 79.96, 76, 29, 74.27, 73.41 (2 Carbons), 72.51, 
72.21, 72.12, 71.10, 70.69, 70.09, 68.14, 66.72, 60.99, 59.50, 51.37, 32.09. ESI/APCI 
calcd for C32H38N12O11F2Na [M+Na]+: m/z 827.2643; measured m/z 827.2652. Yield: 253 
mg (315 mmol, 37%). 
 
4″,6″-Di-O-(2-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin (7f). 1H NMR 
(500 MHz, Metha- nol-D3) δ 7.7 – 7.8 (m, 5H), 7.63 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 7.9 
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Hz, 1H), 7.3 – 7.5 (m, 6H), 7.57 (dd, J = 8.4 Hz, J = 1.5 Hz, 1H), 5.26 (d, J = 3.7 Hz, 
1H), 5.22 (d, J = 3.8 Hz, 1H), 4.8 – 4.9 (m, 1H), 4.75 (d, J = 12.8 Hz, 1H), 4.5 – 4.6 (m, 
2H), 4.3 – 4.4 (m, 1H), 4.0 – 4.1 (m, 1H), 3.3 - 3.7 (m, 15H), 2.3 - 2.4 (m, 1H), 1.51 (ddd, 
J = 12.5 Hz 1H). 13C NMR (125 MHz, Methanol-D3) δ 135.35, 135.33, 133.31, 133.19, 
133.17, 133.01, 127.90, 127.60, 127.56, 127.53, 127.38, 127.22, 126.76, 126.35, 125.95, 
125.85, 125.72, 125.67, 125.63, 125.55, 101.00, 98.28, 83.72, 79.97, 76.19, 74.18 (2 
Carbons), 73.35, 73.04, 72.43,  72.04, 71.06,  70.62,  70.08,  68.02,  66.79,  60.85,  59.40,  
51.32,  31.96.  ESI/APCI  calcd  for C40H44N12O11Na [M+Na]+: 891.3150 m/z ; measured 
891.3111 m/z. Yield: 302 mg (349 mmol, 41%). 
 
4″,6″-Di-O-(1-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin (7g). 1H NMR 
(500 MHz, Metha- nol-D3) δ 8.13 (d, J = 8.3 Hz, 1H), 7.9 (d, J = 7.7 Hz, 1H), 7.7 – 7.8 
(m, 4H), 7.4 – 7.5 (m, 6H), 7.29 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 6.6 Hz, 1H), 5.25 (d, J = 
3.3 Hz, 1H), 5.1 – 5.2 (m, 2H), 5.01 (d, J = 12.2 Hz, 1H), 4.6 – 4.7 (m, 2H), 4.3 – 4.4 (m, 
1H), 4.0 – 4.1 (m, 1H), 3.3 - 3.7 (m, 14H), 2.9 (dd, J = 13.2 Hz, J = 8.1 Hz, 1H), 2.3 - 2.4 
(m, 1H), 1.52 (ddd, J = 12.5 Hz 1H). 13C NMR (125 MHz, Methanol-D3) δ 133.93, 
133.76, 133.45, 133.40, 131.74, 131.65, 128.43, 128.28, 128.23, 128.07, 126.53 (2 
Carbons), 125.86, 125.80, 125.48, 125.32, 124.82, 124.80, 123.87, 123.71, 100.95, 98.23, 
83.66, 79.83, 75.51, 74.14, 73.33, 72.40, 72.02, 71.86, 71.36, 71.23, 70.60, 70.07, 68.11, 
66.95, 60.86, 59.38, 51.30, 31.95. ESI/APCI calcd for C40H44N12O11Na [M+Na]+: 
891.3145 m/z; measured 891.3164 m/z. Yield: 318 mg (366 mmol, 43%). 
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4″,6″-Di-O-(3-phenylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7h). 1H NMR (500 
MHz, Methanol-D3) δ 7.3 – 7.6 (m, 17H), 7.21 (d, J = 7.6 Hz, 1H), 5.26 (d, J = 3.7 Hz, 
1H), 5.17 (d, J = 3.8 Hz, 1H), 4.83 (d, J = 11.0 Hz, 1H), 4.68 (d, J = 12.0 Hz, 1H), 4.61 
(d, J = 11.0 Hz, 1H), 4.53 (d, J = 12.1 Hz, 1H), 4.3 – 4.4 (m, 1H), 4.0 – 4.1 (m, 1H), 3.3 - 
3.7 (m, 15H), 2.3 - 2.4 (m, 1H), 1.51 (ddd, J = 12.2 Hz 1H). 13C NMR (125 MHz, 
Methanol-D3) δ 141.25, 141.18, 140.85, 140.79, 138.56 (2 Carbons), 128.55, 128.46 (2 
Car-bons), 128.43 (3 Carbons), 127.00, 126.96, 126.73, 126.67, 126.64 (4 Carbons), 
126.42, 126.34, 126.10, 126.06, 100.99, 98.25, 83.70, 79.87, 76.39, 74.20, 74.16, 73.34, 
72.83, 72.41, 72.02, 71.04, 70.61, 70.01, 68.10, 66.77, 60.90, 59.40, 51.30, 31.98. 
ESI/APCI calcd for C44H48N12O11Na [M+Na]+ 943.3463: m/z ; measured 943.3355 m/z. 
Yield: 204 mg (221 mmol, 26%). 
 
5, 2′, 3′, 4′, 2″- Penta-O-methyl-4″,6″-di-O-benzyl-1,3,6′,3″-tetraazidokanamycin 
(8a). 1H NMR (300 MHz, Chloroform-D) δ 7.2 – 7.4 (m, 10H), 5.59 (d, J = 3.3 Hz, 1H), 
5.43 (d, J = 3.9 Hz, 1H), 4.78 (d, J = 10.8 Hz, 1H), 4.64 (d, J = 12.0 Hz, 1H), 4.4 – 4.5 
(m, 2H), 4.0 – 4.2 (m, 2H), 3.4 - 3.8 (m, 28H), 3.1 – 3.3 (m, 2H), 2.3 - 2.4 (m, 1H), 1.5 – 
1.6 (m, 1H). 13C NMR (75 MHz, Chloroform-D) δ 138.06, 137.89, 128.51 (2 Carbons), 
128.39 (2 Carbons), 128.16 (2 Carbons), 128.01 (2 Carbons), 127.91, 127.83, 97.03, 
95.53, 84.58, 83.51, 81.81, 80.53, 80.41, 77.83, 77.31, 76.15, 74.79, 73.63, 70.66, 70.24, 
68.10, 65.19, 61.27, 61.02, 60.88, 60.71, 60.66, 59.29, 59.15, 51.33, 32.63. ESI/APCI 
calcd for C37H50N12O11Na [M+Na]+: m/z 861.3614; measured m/z 861.3640. Yield: 344 
mg (410 mmol, 63%). 
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4″,6″-Di-O-benzylkanamycin (7). 1H NMR (300 MHz, D2O) δ 7.2 – 7.4 (m, 8H), 7.1 – 
7.2 (m, 2H), 5.44 (d, J = 3.9 Hz, 1H), 5.01 (d, J = 3.6 Hz, 1H), 4.5 – 4.6 (m, 2H), 4.3 – 
4.4 (m, 2H), 4.0 – 4.1 (m, 1H), 3.4 - 3.9 (m, 12H), 3.2 - 3.3 (m, 2H), 3.0 - 3.1 (m, 2H), 
2.4 - 2.5 (m, 1H), 1.84 (ddd, J = 12.9 Hz 1H). 13C NMR (75 MHz, D2O) δ 136.68, 
136.23, 128.98 (2 Carbons), 128.95 (3 Carbons), 128.89 (2 Carbons), 128.73 (2 Carbons), 
128.66, 100.53, 96.31, 83.90, 78.10, 74.45, 73.33, 73.23, 72.76, 72.09, 71.01, 70.80, 
68.69, 68.08, 67.49, 54.23, 49.89, 47.84, 44.75, 40.36, 27.61. ESI/APCI calcd for 
C32H49N4O11 [MH]+: m/z 665.3392; measured m/z 665.3407. Yield: 99 mg (122 mmol, 
89%). 
 
5, 2′, 3′, 4′, 2″- Penta-O-methyl-4″,6″-di-O-benzylkanamycin (8). 1H NMR (300 
MHz, D2O) δ 7.1 – 7.4 (m, 10H), 5.43 (d, J = 3.3 Hz, 1H), 5.23 (d, J = 3.0 Hz, 1H), 4.4 – 
4.6 (m, 4H), 3.1 - 3.9 (m, 32H), 2.3 - 2.4 (m, 1H), 1.74 (ddd, J = 12.3 Hz 1H). 13C NMR 
(75 MHz, D2O) δ 136.64, 136.26, 129.05 (2 Carbons), 128.96 (2 Carbons), 128.90, 
128.82 (2 Carbons), 128.69 (2 Carbons), 128.63, 97.99, 95.10, 82.61, 81.44, 
81.31, 79.85, 79.68, 78.56, 75.78, 74.50, 73.38, 73.16, 71.38, 68.29, 67.10, 60.19, 59.98, 
59.86, 59.63, 58.36, 53.04, 49.68, 48.15, 40.09, 28.18.  ESI/APCI calcd for C37H59N4O11 
[MH]+: m/z 735.4175; measured m/z 735.4196. Yield: 130 mg (148 mmol, 92%). 
 
5, 2′, 3′, 4′, 2″- Penta-O-methyl-kanamycin (9). 1H NMR (300 MHz, D2O) 5.46 (d, J = 
3.3 Hz, 1H), 5.35 (d, J = 3.3 Hz, 1H), 4.00 (t, J = 9.9 Hz, 1H), 3.1 - 3.9 (m, 31H), 2.3 - 
2.4 (m, 1H), 1.83 (ddd, J = 12.3 Hz 1H). 13C NMR (75 MHz, D2O) δ 98.30, 94.44, 81.57, 
81.41, 80.60, 79.81, 79.67, 78.70, 74.80, 73.02, 68.45, 65.26, 60.19, 59.97 (2 Carbons), 
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59.59, 59.52, 57.11, 53.82, 49.73, 47.85, 40.10, 27.44. ESI/APCI calcd for C23H47N4O11 
[MH]+: m/z 555.3236; measured m/z 555.3234. Yield: 14 mg (20 mmol, 27%). 
 
4″,6″-Di-O-(4-methoxybenzyl) kanamycin (10). 1H NMR (500 MHz, D2O) δ 6.94 (d, J 
= 8.6 Hz, 2H), 6.63 (d, J = 8.6 Hz, 2H), 6.4 – 6.5 (m, 4H), 5.18 (d, J = 3.6 Hz, 1H), 4.68 
(m, 1H, overlapped with H2O), 4.24 (d, J = 11.8 Hz, 1H), 4.03 (d, J = 10.4 Hz, 1H), 3.97 
(d, J = 11.5 Hz, 1H), 3.75 (d, J = 10.4 Hz, 1H), 2.7 - 3.7 (m, 23H), 2.1 - 2.2 (m, 1H), 1.51 
(ddd, J = 12.4 Hz 1H). 13C NMR (125 MHz, D2O) δ 158.61, 158.48, 130.71 (2 Carbons), 
130.01 (2 Carbons), 128.28, 128.13, 113.59 (2 Carbons), 113.54 (2 Carbons), 100.34, 
96.00, 83.63, 77.57, 73.65, 72.41 (2 Carbons), 72.09, 71.53, 70.42 (2 Carbons), 70.36, 
69.25, 67.70, 65.80, 54.79, 54.63, 53.75, 49.47, 47.36, 39.91. ESI/APCI calcd for 
C34H52N4O13Na [M+Na]+: 747.3423 m/z ; measured 747.3436 m/z. Yield: 173 mg (199 
mmol, 54%). 
 
4″,6″-Di-O-(4-methylbenzyl) kanamycin (11). 1H NMR (500 MHz, D2O) δ 7.23 (d, J = 
7.9 Hz, 2H), 7.13 (d, J = 7.4 Hz, 4H), 7.13 (d, J = 7.9 Hz, 2H), 5.49 (d, J = 4.0 Hz, 1H), 
5.05 (d, J = 3.7 Hz, 1H), 4.54 (d, J = 11.6 Hz, 1H), 4.47 (d, J = 10.8 Hz, 1H), 4.36 (d, J = 
11.6 Hz, 1H), 4.25 (d, J = 10.8 Hz, 1H), 4.0 – 4.1 (m, 1H), 3.8 – 4.0 (m, 4H), 3.6 - 3.7 
(m, 4H), 3.4 - 3.5 (m, 5H), 3.2 - 3.3 (m, 2H), 3.1 - 3.2 (m, 1H), 
2.4 - 2.5 (m, 1H), 2.25 (s, 3H), 2.18 (s, 3H), 1.88 (ddd, J = 12.5 Hz 1H). 13C NMR (125 
MHz, D2O) δ 139.12, 138.86, 133.37, 133.08, 129.38 (4 Carbons), 129.19 (2 Carbons), 
128.75 (2 Carbons), 100.44, 96.28, 83.83, 78.03, 74.21, 73.13, 72.88, 72.74, 72.02,  
70.94, 70.79, 70.76,  68.63, 68.02, 66.93, 54.20, 49.83, 47.81, 40.33, 27.56, 20.30, 20.28. 
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ESI/APCI calcd for C34H53N4O11 [MH]+: 693.3705 m/z ; measured 693.3731 m/z. Yield: 
198 mg (236 mmol, 88%). 
 
4″,6″-Di-O-(4-chlorobenzyl) kanamycin (12). 1H NMR (500 MHz, D2O) δ 7.2 – 7.3 
(m, 6H), 7.07 (d, J = 8.4 Hz 2H), 5.44 (d, J = 3.9 Hz, 1H), 5.44 (d, J = 3.6 Hz, 1H), 4.5 – 
4.6 (m, 2H), 4.36 (d, J = 11.9 Hz, 1H), 4.27 (d, J = 11.3 Hz, 1H), 4.0 – 4.1 (m, 1H), 4.0 – 
4.1 (m, 1H), 3.1 - 3.9 (m, 15H), 2.4 - 2.5 (m, 1H), 1.81 (ddd, J = 12.5 Hz 1H). 13C NMR 
(125 MHz, D2O) δ 135.06, 134.82, 133.73, 133.66, 130.50 (2 Carbons), 129.64 (2 
Carbons), 128.72 (2 Carbons), 128.69 (2 Carbons), 100.40, 96.56, 84.09, 78.39, 
73.58, 73.51, 73.02, 72.24, 71.99, 70.77 (4 Carbons), 68.61, 68.12, 67.09, 54.20, 49.87, 
47.96, 40.32, 28.05. ESI/APCI calcd for C32H47Cl2N4O11 [MH]+: 733.2613 m/z ; 
measured 733.2621 m/z. Yield: 53 mg (60 mmol, 58%). 
 
4″,6″-Di-O-(4-flurobenzyl) kanamycin (13). 1H NMR (500 MHz, D2O) 7.3 – 7.4 (m, 
2H), 7.1 – 7.2 (m, 2H), 7.0 – 7.1 (m, 4H), 5.47 (d, J = 3.9 Hz, 1H), 5.03 (d, J = 3.6 Hz, 
1H), 4.5 – 4.6 (m, 2H), 4.41 (d, J = 11.6 Hz, 1H), 4.34 (d, J = 11.0 Hz, 1H), 4.0 – 4.1 (m, 
1H), 3.3 - 3.9 (m, 16H), 2.3 - 2.4 (m, 1H), 1.82 (ddd, J = 12.5 Hz 1H). 13C NMR (125 
MHz, D2O) δ 162.57 (d, JCF = 244.3 Hz), 162.49 (d, JCF = 244.3 Hz), 132.46 (d, JCF = 2.8 
Hz), 132.12 (d, JCF = 2.8 Hz), 130.94 (d, JCF = 8.4 Hz, 2 Carbons), 130.43 (d, JCF = 
8.4 Hz, 2 Carbons), 115.49 (d, JCF = 21.6 Hz, 2 Carbons), 115.43 (d, JCF = 21.6 Hz, 2 
Carbons), 100.44, 98.51, 83.98, 78.40, 73.60, 73.31, 72.87, 72.34, 72.01, 70.83, 70.75, 
70.70, 68.62, 68.07, 67.11, 54.17, 49.58, 47.87, 40.26, 27.88. ESI/APCI calcd for 
C32H47F2N4O11 [MH]+: 701.3204 m/z; measured 701.3200 m/z. Yield: 66 mg (78 mmol, 
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71%). 
 
4″,6″-Di-O-(2-naphthalenmethyl) kanamycin (14). 1H NMR (500 MHz, D2O) δ 7.2 – 
7.7 (m, 13H), 7.00 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 5.39 (d, J = 3.9 Hz, 1H), 5.06 (d, J = 
3.6 Hz, 1H), 4.6 – 4.7 (m, 2H), 4.37 (d, J = 11.9 Hz, 1H), 4.28 (d, J = 11.4 Hz, 1H), 4.0 – 
4.1 (m, 1H), 3.0 - 3.9 (m, 16H), 2.3 - 2.4 (m, 1H), 1.86 (ddd, J = 12.5 Hz 1H). 13C NMR 
(125 MHz, D2O) δ 133.79, 133.50, 132.84, 132.77, 132.69, 132.53, 128.47, 128.31, 
127.99, 127.81 (2 Carbons), 127.61, 127.60, 127.01, 126.62, 126.55, 126.52 (2 
Carbons), 126.47, 125.62, 100.43, 96.46, 83.87, 77.83, 73.24, 73.04, 72.98, 71.90, 70.90, 
70.68, 70.65,68.59, 68.03, 66.99, 54.24, 49.76, 47.92, 40.29, 27.54.  ESI/APCI calcd for 
C40H53N4O11  [MH]+: 765.3705 m/z ; measured 765.3755 m/z. Yield: 85 mg (94 mmol, 
72%). 
 
4″,6″-Di-O-(1-naphthalenmethyl) kanamycin (15). 1H NMR (500 MHz, D2O) δ 7.87 
(d, J = 8.3 Hz, 1H), 7.7 – 7.8 (m, 4H), 7.5 – 7.6 (m, 2H), 7.2 – 7.5 (m, 6H), 7.06 (d, J = 
6.8 Hz, 1H), 5.17 (d, J = 3.9 Hz, 1H), 5.05 (d, J = 3.6 Hz, 1H), 4.7 – 4.8 (m, 2H), 4.3 – 
4.4 (m, 2H), 3.9 – 4.0 (m, 1H), 3.3 - 3.7 (m, 15H), 2.9 - 3.0 (m, 1H), 2.4 - 2.5 (m, 1H), 
1.84 (ddd, J = 12.5 Hz 1H). 13C NMR (125 MHz, D2O) δ 133.49, 133.38, 131.85, 131.80, 
131.35, 130.65, 129.34, 129.29, 128.75, 128.68, 127.94, 127.28, 126.92, 126.68, 126.29, 
126.11, 125.46, 125.34, 123.65, 123.14, 100.07, 96.06, 83.59, 77.81, 73.81, 72.77, 
72.11, 71.97, 71.09, 71.06, 70.71, 70.61, 68.46, 67.89, 67.70, 54.33, 49.68, 47.70, 40.21, 
27.51. ESI/ APCI calcd for C40H53N4O11 [MH]+: 765.3705 m/z; measured 765.3704 m/z. 
Yield: 209 mg (229 mmol, 42%). 
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4″,6″-Di-O-(3-phenylbenzyl)-kanamycin (16). 1H NMR (500 MHz, D2O) δ 7.42 (s, 
1H), 7.1 – 7.4 (m, 16H), 7.03 (d, J = 7.6 Hz, 1H), 5.49 (d, J = 3.9 Hz, 1H), 5.05 (d, J = 
3.4 Hz, 1H), 4.59 (d, J = 12.0 Hz,1H), 4.51 (d, J = 11.1 Hz, 1H), 4.2 – 4.3 (m, 2H), 4.0 – 
4.1 (m, 1H), 3.0 – 3.9 (m, 16H), 2.4 - 2.5 (m, 1H), 1.86 (dd, J = 12.5 Hz, 1H). 13C NMR 
(125 MHz, D2O) δ 140.75, 140.68, 139.89, 139.78, 136.80, 136.78, 129.35, 129.25, 
129.03 (2 Carbons), 128.92 (2 Carbons), 128.12, 127.76, 127.65, 127.23, 127.21, 126.98, 
126.94, 126.84 (2 Carbons), 126.72 (2 Carbons), 126.50, 100.52, 96.86, 83.73, 78.25, 
74.21, 73.28, 73.00 (2 Carbons), 71.96, 70.91, 70.76, 70.68, 68.66, 68.05, 66.91, 54.23, 
49.81, 47.92, 40.26, 27.58. ESI/APCI calcd for C44H57N4O11 [MH]+: 817.4024 m/z; 
measured 817.4005 m/z. Yield: 215 mg (223 mmol, 74%). 
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B-1      1H NMR of 4″,6″-Di-O-benzyl-1,3,6′,3″-tetraazidokanamycin (7a) 
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B-2       13C NMR of 4″,6″-Di-O-benzyl-1,3,6′,3″-tetraazidokanamycin (7a) 
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B-3      1H NMR of 4″,6″-Di-O-(4-methoxybenzyl)-1,3,6′,3″-tetraazidokanamycin (7b) 
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B-4          13C NMR of 4″,6″-Di-O-(4-methoxybenzyl)-1,3,6′,3″-tetraazidokanamycin 
(7b) 
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B-5      1H NMR of 4″,6″-Di-O-(4-methylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7c) 
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B-6       13C NMR of 4″,6″-Di-O-(4-methylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7c) 
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B-7         1H NMR of 4″,6″-Di-O-(4-chlorobenzyl)-1,3,6′,3″-tetraazidokanamycin (7d) 
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B-8         13C NMR of 4″,6″-Di-O-(4-chlorobenzyl)-1,3,6′,3″-tetraazidokanamycin (7d) 
145 
 
 
 
 
 
B-9         1H NMR of 4″,6″-Di-O-(4-flurobenzyl)-1,3,6′,3″-tetraazidokanamycin (7e) 
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B-10      13C NMR of 4″,6″-Di-O-(4-flurobenzyl)-1,3,6′,3″-tetraazidokanamycin (7e) 
147 
 
 
 
 
 
B-11      1H NMR of 4″,6″-Di-O-(2-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin 
(7f) 
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B-12     13C NMR of 4″,6″-Di-O-(2-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin 
(7f) 
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B-13     1H NMR of 4″,6″-Di-O-(1-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin
(7g) 
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B-14     13C NMR of 4″,6″-Di-O-(1-naphthalenemethyl)-1,3,6′,3″-tetraazidokanamycin 
(7g) 
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B-15    1H NMR of 4″,6″-Di-O-(3-phenylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7h) 
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B-16    13C NMR of 4″,6″-Di-O-(3-phenylbenzyl)-1,3,6′,3″-tetraazidokanamycin (7h) 
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B-17     1H NMR of 5, 2′, 3′, 4′, 2″- Penta-O-methyl-4″,6″-di-O-benzyl-1,3,6′,3″-
tetraazidokanamycin (8a) 
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Table C-1. Antifungal synergistic activities of azoles combined with MAN014a 
Azole 
FIC index 
Candida albicans 
MYA2876 (azole 
susceptible) 
Cryptococcus 
neoformans 
H99 
Rhodotorula 
pilimanae 
Clotrimazole 0.999 0.624 0.626 
Fluconazole 0.250 0.515 0.563 
Itraconazole 0.750 0.751 0.500 
Posaconazole 0.624 0.626 0.751 
 
Voriconazole 0.624 1.00 2.00 
a Combination interactions are classified as synergistically inhibitory if the FICI is ≤0.5, 
indifferent if >0.5 - 4, and antagonistic if >4. 
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